







POSTERS PRESENTATIONS






All posters are available in pdf format at all times on the CTAD22 digital platform.






Poster presentations presented onsite in San Francisco are indicated with this icon 





Posters presented from Tuesday, November 29 at 4pm to Wednesday, November 30 at 6pm

Theme: Clinical Trials: Methodology




	P001: Feasibility of virtual amyloid PET disclosure with cognitively unimpaired research participants <u>Claire Erickson</u> ¹ , Nathaniel Chin ¹ , Hannah Rosario ¹ , Amanda Peterson ¹ , Sterling Johnson ¹ , Lindsay Clark ¹ ¹ University Of Wisconsin-Madison - Madison (United States)
	P002: Using common-close trial designs for efficiently detecting slowing of progression in Alzheimer's disease <u>Lars Lau Raket</u> ¹ , Jeffrey Cummings ² ¹ Novo Nordisk - Søborg (Denmark), ² Chambers-Grundy Center For Transformative Neuroscience, Pam Quirk Brain Health And Biomarker Laboratory, Department Of Brain Health, School Of Integrated Health Sciences, University Of Nevada Las Vegas (unlv) - Las Vegas (United States)
	P003: Evaluating KarXT (xanomeline-trospium) as a treatment for psychosis associated with Alzheimer's disease dementia: design of the phase 3, ADEPT-1, relapse prevention study <u>Carolyn Watson</u> ¹ , Jeffrey Cummings ² , George Grossberg ³ , Minsu Kang ¹ , Ronald Marcus ¹ ¹ Karuna Therapeutics - Boston (United States), ² University Of Nevada Las Vegas School Of Integrated Health Sciences - Las Vegas (United States), ³ Saint Louis University School Of Medicine - Saint Louis (United States)
	P004: Number of Days Between Initial Contact and In-Person Visit Predict Attendance Rates for Potential Alzheimer's Disease Trial Participants <u>Sarah Starling</u> ¹ , Gabriela Munoz ¹ , Miriam Evans ¹ , Jenicka Engler ¹ , Stephanie Rutrick ¹ ¹ Adams Clinical - Watertown (United States)
	P005: Power analysis of a prognostic enrichment procedure based on AD Course Map, a simulation study <u>Etienne Maheux</u> ¹ , Igor Koval ¹ , Juliette Ortholand ¹ , Colin Birkenbihl ² , Vincent Bouteloup ³ , Stanley Durrleman ¹ ¹ Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, Paris (France), ² Fraunhofer Institute for Algorithms and Scientific Computing SCAI - Sankt Augustin (Germany), ³ Université de Bordeaux, Inserm 1219, CIC1401-EC - Bordeaux (France)
	P006: Implementing Novel Clinical Trial Designs in Dementia with Lewy Bodies: A Roadmap to Personalized Medicine <u>Carla Abdelnour</u> ¹ , Jon B. Toledo ² , Daniel Ferreira ³ , Federico Rodríguez-Porcel ⁴ , Parichita Choudhury ⁵ , Maureen Okafor ⁶ , Sonja Scholz ⁷ , Bradley Boeve ⁵ , Irene Litvan ⁸ , James Leverenz ⁹ , Laura Bonanni ¹⁰ , John-Paul Taylor ¹¹ , Simon J. G. Lewis ¹² , Dag Aarsland ¹³ , Kathleen Poston ¹ ¹ Neurology And Neurological Sciences Department, Stanford University - Palo Alto (United States), ² Department Of Neurology University Of Florida College Of Medicine - Gainesville (United States), ³ Division Of Clinical Geriatrics, Department Of Neurobiology, Care Sciences And Society, Karolinska







	<p><i>Institutet - Stockholm (Sweden), ⁴Department Of Neurology, Medical University Of South Carolina - Charleston (United States), ⁵Department Of Neurology, Mayo Clinic - Rochester (United States), ⁶Department Of Neurology, Emory University School Of Medicine - Atlanta (United States), ⁷Neurodegenerative Diseases Research Unit, National Institute Of Neurological Disorders And Stroke. Laboratory Of Neurogenetics, National Institute On Aging - Bethesda (United States), ⁸Parkinson and Other Movement Disorders Center, Department of Neurosciences, University of California San Diego - La Jolla (United States), ⁹Lou Ruvo Center for Brain Health, Neurological Institute, and Department of Neurology. Cleveland Clinic - Cleveland (United States), ¹⁰Department of Neuroscience Imaging and Clinical Sciences and CESI, University G d'Annunzio of Chieti-Pescara - Chieti (Italy), ¹¹Translational and Clinical Research Institute, Newcastle University - Newcastle (United Kingdom), ¹²Forefront Parkinson's Disease Research Clinic, Brain And Mind Centre, University Of Sydney - Camperdown Nsw 2050 (Australia), ¹³Institute of Psychiatry, Psychology, & Neuroscience, King's College London - London (United Kingdom)</i></p>
	<p>P007: Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is commonly misdiagnosed as Alzheimer's disease (AD) and Frontotemporal Dementia (FTD) <u>Spyros Papapetropoulos</u>¹, Angela Pontius², Samantha Zappia¹, Matthew Brennan², Leslie Leahy² ¹Vigil Neuroscience - Cambridge (United States), ²Consultant To Vigil Neuroscience - Cambridge (United States)</p>
	<p>P008: Update on the TOGETHER study: a patient- and investigator-blind, randomized, placebo-controlled study evaluating the efficacy, safety and tolerability of bepranemab, UCB0107, in prodromal-to-mild Alzheimer's disease <u>Matthew E. Barton</u>¹, Bart Van Den Steen², Hans L. G. Van Tricht², William Byrnes¹, Fiona E. Purcell³, Sarah Ann Southcott³, Daniel Raby³, Yaroslav I. Starshinov³, Colin Ewen² ¹UCB Pharma - Raleigh, North Carolina (United States), ²UCB Pharma - Brussels (Belgium), ³ICON plc - Dublin (Ireland)</p>
	<p>P009: The impact of erratic changes on 1 year change in CDR-SB. An exploratory analysis. <u>Alan Kott</u>¹, Xingmei Wang², David Miller² ¹Signant Health - Prague (Czech Republic), ²Signant Health - Blue Bell (United States)</p>
	<p>P010: Early Engagement with the Alzheimer's Disease Community to Gain Insights into Designing the SKYLINE Trial for Pre-symptomatic Alzheimer's Disease <u>Fiona Rose</u>¹, Nancy Lynn², Jessica B. Langbaum³, Carolyn Langlois³, Emma Louise Dodd¹, Jannice Roeser⁴, Gesine Respondek⁴, Susanne Ostrowitzki⁴ ¹Roche Products Ltd - Welwyn Garden City (United Kingdom), ²BrightFocus Foundation - Clarksburg (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴F. Hoffmann-La Roche Ltd - Basel (Switzerland)</p>
	<p>P011: Contrasting the NIH Toolbox Emotional Battery Outcomes Between Caucasians and African American Older Adult Participants in a Randomized Clinical Trial: I-CONNECT Study <u>Kexin Yu</u>¹, Lisa Silbert^{1,2}, Laura Struble³, Hiroko H. Dodge¹ ¹NIA-Layton Aging and Alzheimer's Disease Center, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA - Portland (United States), ²Portland Veterans Affairs Health Care System, Portland, OR, USA - Portland (United States), ³Department of Health Behavior and Biological Sciences, School of Nursing, University of Michigan Ann Arbor, Michigan, USA - Ann Arbor (United States)</p>
	<p>P012: Development and Feasibility of a Data-Driven Approach to Preclinical Alzheimer's Disease Clinical Trial Recruitment through Centralized Pre-screening Data Collection</p>


	<p><u>Dylan Kirn</u>¹, <u>Joshua Grill</u>², <u>Paul Aisen</u>³, <u>Karin Ernstrom</u>³, <u>Seth Gale</u>⁴, <u>Judith Heidebrink</u>⁵, <u>Gregory Jicha</u>⁶, <u>Gustavo Jimenez-Maggiore</u>³, <u>Leigh Johnson</u>⁷, <u>Elaine Peskind</u>⁸, <u>Raymond Scott Turner</u>⁹, <u>David Sultzer</u>², <u>Shunran Wang</u>³, <u>Reisa Sperling</u>⁴, <u>Rema Raman</u>³</p> <p>¹<i>Department of Neurology, Massachusetts General Hospital - Boston (United States)</i>, ²<i>Institute for Memory Impairments and Neurological Disorders, Department of Psychiatry and Human Behavior, University of California Irvine - Irvine (United States)</i>, ³<i>Alzheimer's Therapeutic Research Institute, University of Southern California - San Diego (United States)</i>, ⁴<i>Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States)</i>, ⁵<i>Department of Neurology, University of Michigan - Ann Arbor (United States)</i>, ⁶<i>Sanders-Brown Center on Aging, University of Kentucky - Lexington (United States)</i>, ⁷<i>Institute for Translational Research, University of North Texas Health Science Center - Fort Worth (United States)</i>, ⁸<i>VA Northwest Mental Illness Research, Education, and Clinical Center (MIRECC), VA Puget Sound Health Care System - Seattle (United States)</i>, ⁹<i>Department of Neurology, Georgetown University Medical Center - Washington D.c. (United States)</i></p>
	<p>P013: Design of Pragmatic Trials for Interventions Targeting Cognitive Decline: Benchmarks from the COcoa Supplement and Multivitamin Outcomes Study of the Mind (COSMOS-Mind)</p> <p><u>Mark Espeland</u>¹, <u>Joann Manson</u>², <u>Steve Rapp</u>¹, <u>Howard Sesso</u>², <u>Sarah Gaussoin</u>¹, <u>Sally Shumaker</u>¹, <u>Laura Baker</u>¹</p> <p>¹<i>Wake Forest School of Medicine - Winston-Salem (United States)</i>, ²<i>Brigham and Women's Hospital - Boston (United States)</i></p>
	<p>P014: Use of the Digit Symbol Substitution Test (DSST) as an entry criterion for a cognitive study of a β2-AR agonist.</p> <p><u>Gabriel Vargas</u>¹, <u>Renee Martin</u>¹, <u>Peter Butera</u>¹, <u>Judy Reynolds</u>¹, <u>Tim Anderson</u>², <u>Aliya Asher</u>³, <u>Erik Buntinx</u>⁴, <u>Anthony Ford</u>¹, <u>John Harrison</u>⁵</p> <p>¹<i>CuraSen - San Carlos (United States)</i>, ²<i>New Zealand Brain Research Institute - Christchurch (New Zealand)</i>, ³<i>MAC Clinical Research - Manchester (United Kingdom)</i>, ⁴<i>Anima Research Center - Alken (Belgium)</i>, ⁵<i>Metis Cognition - Kilmington Common (United Kingdom)</i></p>
	<p>P015: Improving the accuracy and precision of Lecanemab treatment effect assessment using Alzheimer's disease prognostic covariate</p> <p><u>Viswanath Devanarayan</u>¹, <u>Liang Zhu</u>¹, <u>Michael Irizarry</u>¹, <u>Lynn Kramer</u>¹, <u>Shobha Dhadha</u>¹</p> <p>¹<i>Eisai, Inc. - Nutley (United States)</i></p>
	<p>P016: Enhancing Recruitment of Underrepresented Communities with the Deployment of a Mobile Research Unit.</p> <p><u>Jill Smith</u>¹, <u>John Dwyer</u>¹, <u>Dawn Batchuluun</u>¹, <u>Tamiko Magee Rodgers</u>¹, <u>Leigh Zisko</u>¹</p> <p>¹<i>Global Alzheimer's Platform Foundation - Washington Dc (United States)</i></p>
	<p>P017: Genotypic effects of the TOMM40'523 variant and APOE on longitudinal cognitive change over 4 years: The TOMMORROW Study</p> <p><u>Haotian Zou</u>¹, <u>Sheng Luo</u>², <u>Michael W. Lutz</u>², <u>David A. Bennett</u>³, <u>Brenda L. Plassman</u>², <u>Kathleen A. Welsh-Bohmer</u>²</p> <p>¹<i>University of North Carolina- Chapel Hill - Chapel Hill (United States)</i>, ²<i>Duke University - Durham (United States)</i>, ³<i>Rush University - Chicago (United States)</i></p>
	<p>P018: Racial/ethnic Group Differences in Response Rate to a Mail Invitation to Participate in a Lifestyle Intervention Trial to Prevent Cognitive Decline (U.S. POINTER Trial)</p> <p><u>Valory Pavlik</u>¹, <u>Melissa Yu</u>¹, <u>Ashley Alexander</u>², <u>John Valenta</u>², <u>Richard Elbein</u>³, <u>Annmarie McDonald</u>³</p> <p>¹<i>Baylor College Of Medicine - Houston (United States)</i>, ²<i>Kelsey Research Foundation - Houston (United States)</i>, ³<i>Alzheimer's Association - Houston (United States)</i></p>
	<p>P019: Development of an abbreviated pre-screening cognitive battery to enhance referral to clinical trials</p>

	<p><u>Abigail O Connell</u>¹, <u>Eric Fischer</u>¹, <u>Lauren Latham</u>¹, <u>Laura Baker</u>¹, <u>Suzanne Craft</u>¹ ¹<i>Wake Forest Alzheimer's Disease Research Center - Winston-Salem (United States)</i></p>
	<p>P020: Rescreening on RBANS delayed memory index? Forget about it! <u>Marwan N Sabbagh</u>¹, <u>Wojciech Michalak</u>², <u>Charlotte Thim Hansen</u>², <u>Lars Lau Raket</u>², <u>Christian Ahmad Wichmann</u>², <u>Alice Clark</u>² ¹<i>Barrow Neurological Institute - Phoenix, Arizona (United States)</i>, ²<i>Novo Nordisk A/S - Søborg (Denmark)</i></p>
	<p>P021: Using an end-to-end deep learning model in older adults with MCI to identify AD risk factors on chromosome 19 that exacerbate cognitive decline <u>Jinhyeong Bae</u>¹, <u>Liana Apostolova</u>¹, <u>Valentin Pentchev</u>¹, <u>Dustin Hammers</u>¹, <u>Angelina Polsinelli</u>¹, <u>Kelly Nudelman</u>¹, <u>Andrew Saykin</u>¹, <u>Kwangsik Nho</u>¹ ¹<i>IUPUI - Indianapolis (United States)</i></p>
	<p>P022: Pandemic Effects on Duplicate Subjects in Clinical Trials of Alzheimer's Disease <u>Thomas Shiovitz</u>¹, <u>Chelsea Steinmetz</u>², <u>Brittany Steinmiller</u>² ¹<i>California Neuroscience Research, CTSdatabase LLC - Sherman Oaks, Ca (United States minor outlying islands)</i>, ²<i>CTSdatabase LLC - Sherman Oaks, Ca (United States minor outlying islands)</i></p>
	<p>P023: The Time Component Test is Inherently Meaningful Because it Combines Evidence Across Outcomes to Measure the Impact of Treatment on Progression Rate in Degenerative Diseases <u>Samuel Dickson</u>¹, <u>Suzanne Hendrix</u>¹ ¹<i>Pentara Corporation - Salt Lake City (United States)</i></p>







Theme: New Therapies and Clinical Trials

	<p>P024: Potential Reversal of Alzheimer's Disease pathology by Antibody TB006 Targeting Galectin-3, a Major Cause of Oligomerization of Amyloid Proteins <u>Suhail Rasool</u>¹, <u>Jenny Johansson</u>¹, <u>Ludmila Voloboueva</u>¹, <u>Sangmi Lee</u>¹, <u>Nancy Lan</u>¹, <u>Taufeeq Ahmed</u>¹, <u>Dongxu Sun</u>¹ ¹<i>Truebinding Inc. - Foster City (United States)</i></p>
	<p>P025: Whole-Brain Low-Intensity Pulsed Ultrasound Therapy For Early Stage Of Alzheimer's Disease (LIPUS-AD): A Randomized, Double-Blind, Placebo-Controlled Trial <u>Hiroaki Shimokawa</u>^{1,2}, <u>Tomohiko Shindo</u>¹, <u>Aiko Ishiki</u>³, <u>Naoki Tomita</u>³, <u>Kumiko Eguchi</u>¹, <u>Takashi Shiroto</u>¹, <u>Jun Takahashi</u>¹, <u>Kentaro Shiratsuchi</u>⁴, <u>Satoshi Yasuda</u>¹, <u>Hiroyuki Arai</u>³ ¹<i>Tohoku University Graduate School Of Medicine - Sendai (Japan)</i>, ²<i>International University of Health and Welfare - Narita (Japan)</i>, ³<i>Institute Of Development, Aging And Cancer, Tohoku University - Sendai (Japan)</i>, ⁴<i>Sound Wave Innovation, Co. - Tokyo (Japan)</i></p>
	<p>P026: CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with mild cognitive impairment due to Alzheimer's disease <u>Alan Lerner</u>^{1,2}, <u>Steven Arnold</u>³, <u>Erin Maxfield</u>⁴, <u>Aaron Koenig</u>³, <u>Maria Toth</u>¹, <u>Brooke Fortin</u>³, <u>Bianca Trombetta</u>³, <u>Andrew Pieper</u>^{5,6,7,8}, <u>Curtis Tatsuoka</u>⁹, <u>Irina Pikuleva</u>⁴ ¹<i>Brain Health And Memory Center, Neurological Institute, University Hospitals Cleveland Medical Center - Cleveland (United States)</i>, ²<i>Department of Neurology, Case Western Reserve University - Cleveland (United States)</i>, ³<i>Alzheimer's Clinical And Translational Research Unit, Massachusetts General Hospital - Boston (United States)</i>, ⁴<i>Department Of Ophthalmology And Visual Sciences, Case Western Reserve</i></p>



	<p>University - Cleveland (United States), ⁵Harrington Discovery Institute, University Hospitals Cleveland Medical Center - Cleveland (United States), ⁶Department Of Psychiatry, Case Western Reserve University - Cleveland (United States), ⁷Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center - Cleveland (United States), ⁸Institute For Transformative Molecular Medicine, Case Western Reserve University - Cleveland (United States), ⁹Department Of Population And Quantitative Health Sciences, Case Western Reserve University - Cleveland (United States)</p>
	<p>P027: A Phase 2 Study of the Sigma-2 Ligand CT1812 in Participants with Dementia with Lewy Bodies <u>James Galvin</u>¹, Magdalena Tolea¹, Michael Grundman², Mary Hamby³, Anthony Caggiano⁴ ¹Comprehensive Center for Brain Health, Department of Neurology, University of Miami Miller School of Medicine - Boca Raton, Fl (United States), ²Grnd Partners - San Diego, Ca (United States), ³Cognition Therapeutics - Pittsburgh, Pa (United States), ⁴Cognition Therapeutics - Purchase, Ny (United States)</p>
	<p>P028: ALZLIGHT Pilot: Preliminary Report on Safety and Feasibility From a Randomized Controlled Trial of Light-Based Brain Stimulation With 40 Hz Invisible Spectral Flickering Light in Patients With Mild-to-Moderate Alzheimer's Disease <u>Mikkel Pejstrup Agger</u>^{1,2}, Marcus Schultz Carstensen³, Maibritt Horning^{1,2}, Else Rubæk Danielsen⁴, Anders Ohlhues Baandrup⁴, Mai Nguyen⁵, Mark Alexander Henney⁵, Christopher Ravn Boe Jensen⁵, Kristoffer Hougaard Madsen^{6,7}, Troels Wesenberg Kjær^{1,2}, Kamilla Miskowiak^{8,9}, Paul Michael Petersen³, Peter Høgh^{1,2} ¹Department of Neurology, Zealand University Hospital - Roskilde (Denmark), ²Department of Clinical Medicine, University of Copenhagen - Copenhagen (Denmark), ³Dept. of Electrical and Photonics Engineering, Technical University of Denmark - Kgs. Lyngby (Denmark), ⁴Department of Radiology, Zealand University Hospital - Roskilde (Denmark), ⁵OptoCeutics ApS - Copenhagen (Denmark), ⁶Dept. of Applied Mathematics and Computer Science, Technical University of Denmark - Copenhagen (Denmark), ⁷Danish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital - Amager and Hvidovre - Copenhagen (Denmark), ⁸Neurocognition and Emotion in Affective Disorders (NEAD) Group, Copenhagen Affective Disorder research Centre (CADIC), Psychiatric Centre Copenhagen - Copenhagen (Denmark), ⁹Department of Psychology, University of Copenhagen - Copenhagen (Denmark)</p>
	<p>P029: Characterization of amyloid-beta protofibrils in Alzheimer's disease brain and the unique binding properties of lecanemab <u>Lars Lannfelt</u>¹, Linda Söderberg¹, Malin Johannesson¹, Nicolas Fritz¹, Eleni Gkanatsiou¹, Adeline Rachalski¹, Helen Kylefjord¹, Gunilla Osswald¹, Christer Möller¹ ¹BioArctic AB - Stockholm (Sweden)</p>
	<p>P030: AD101 - the clinical profile of a new, first-in-class treatment for Alzheimer's Disease <u>Jan Burmeister</u>¹, Serge Gauthier², Sharon Rogers¹ ¹AmyriAD Pharma, Inc. - Los Angeles (United States), ²McGill University - Montréal (Canada)</p>
	<p>P031: Impact of pimavanserin on cognitive measures in patients with neuropsychiatric manifestations of Alzheimer's disease: results from 3 placebo-controlled clinical studies <u>Clive Ballard</u>¹, Victor Abler², Sanjeev Pathak², Pierre Tariot¹, Bruce Coate², Ana Berrio², James M Youakim², Srdjan Stankovic² ¹Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), ²ACADIA Pharmaceuticals Inc. - Princeton (United States)</p>
	<p>P032: Impact of pimavanserin treatment on motor function in patients with neuropsychiatric manifestations of Alzheimer's disease: results from 3 clinical studies Daniel Weintraub¹, <u>Victor Abler</u>², Clive Ballard¹, Bruce Coate², Ana Berrio², Sanjeev Pathak², James M Youakim², Srdjan Stankovic²</p>

	¹ Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania - Philadelphia (United States), ² ACADIA Pharmaceuticals Inc. - Princeton (United States)
	P033: Intravenous treatment with BRICHOS molecular chaperone designed against amyloid-β toxicity improves features of Alzheimer disease pathology in mice <u>Jan Johansson</u> ¹ ¹ Karolinska Institutet - Huddinge (Sweden)

Theme: Clinical Trials Results

	P034: Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias <u>Elisabeth Rindner</u> ¹ , Kennedy Mahdavi ^{1,2} , Jonathan Haroon ¹ , Kaya Jordan ¹ , Margaret Zielinski ¹ , Victoria Venkatraman ^{1,3} , Dayan Goodenowe ⁴ , Clarence Ahlem ⁵ , Christopher Reading ⁵ , Joseph Palumbo ⁵ , Bijan Pourat ⁶ , Sheldon Jordan ^{1,3} ¹ The Regenesys Project - Santa Monica (United States), ² Synaptec Network, - Santa Monica (United States), ³ Synaptec Network - Santa Monica (United States), ⁴ Prodrome Sciences USA LLC - Temecula (United States), ⁵ Biovie Inc. - Carson City (United States), ⁶ Pourat MD - Beverly Hills (United States)
	P035: Meta-analysis of high-clearance anti-amyloid immunotherapies trials in early Alzheimer's disease: a significant clinical effect but a low benefit/risk ratio <u>Nicolas Villain</u> ¹ , Vincent Planche ² ¹ Ap-Hp Sorbonne Université, Hôpital Pitié-Salpêtrière, Department Of Neurology, Institute Of Memory And Alzheimer's Disease - Paris (France), ² Univ. Bordeaux, Cnrs, Imn, Umr 5293 - Bordeaux (France)
	P036: LilyPADD Trial: Targeting Hippocampal Hyperconnectivity in Cognitively Normal Older Adults at Risk for Alzheimer's Disease with AGB101 Shi-Jiang Li ¹ , Arnold Bakker ² , Yang Wang ¹ , B. Doug Ward ¹ , Shelby Schold ¹ , Piero Antuono ¹ , E. G. Deluque ¹ , Malgorzata Franczak ¹ , Joseph Goveas ¹ ¹ Medical College Of Wisconsin, ² Johns Hopkins University
	P037: Planning the next generation of Alzheimer's Disease clinical trials using diverse patient-level database from the Critical Path for Alzheimer's Disease (CPAD) Consortium <u>Sudhir Sivakumar</u> ¹ , Nicholas Cullen ¹ , Zihan Cui ¹ , Eileen Priest ¹ , Corissa Lau ¹ , Hazel White ¹ , Michael Irizarry ² , Klaus Romero ¹ , Yashmin Karten ¹ ¹ Critical Path Institute - Tucson (United States), ² Eisai Inc. - Nutley (United States)
	P038: Critical Path for Alzheimer's Disease (CPAD) Consortium: Accelerating and de-risking therapeutic development in AD by building regulatory decision-making tools <u>Sudhir Sivakumar</u> ¹ , Nicholas Cullen ¹ , Corissa Lau ¹ , Eileen Priest ¹ , Hazel White ¹ , Michael Irizarry ² , Klaus Romero ¹ , Yashmin Karten ¹ ¹ Critical Path Institute - Tucson (United States), ² Eisai - Nutley (United States)
	P039: Effectiveness of a digitally supported care management program for family and other informal dementia caregivers: baseline data and first results from the GAIN randomized <u>Ingo Kilimann</u> ¹ , Olga Klein ² , Jochen René Thyrian ³ , Melanie Boekholt ³ , Stefan Teipel ¹ , Wolfgang Hoffmann ⁴ ¹ Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/greifswald And University Medical Center Rostock, Department Psychosomatics And Psychotherapy - Rostock (Germany), ² Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/greifswald - Rostock






	(Germany), ³ Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/greifswald - Greifswald (Germany), ⁴ Deutsches Zentrum Für Neurodegenerative Erkrankungen Dzne Rostock/greifswald And University Hospital Greifswald, Institute For Community Medicine - Greifswald (Germany)
	P040: Repeat IV and SC dosing of the Anti-Sortilin Antibody AL101 <u>Michael Ward</u> ¹ , Felix Yeh ¹ , Daniel Maslyar ¹ , Yijie Liao ¹ , Hua Long ¹ , Hernan Picard ¹ , Michael Kurnellas ¹ , Mayura Vadhavkar ¹ , Amber Silva ¹ ¹ Alector, Inc. - South San Francisco (United States)
	P041: SAL-AD: A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease <u>Peter Ljubenkov</u> ¹ , Lawren Vandevrede ¹ , Rojas Rojas ¹ , Madison Honey ² , Argentina Lario Lago ¹ , Richard Tsai ³ , Mary Koestler ¹ , Renaud La Joie ¹ , Keith Alan Johnson ⁴ , Li Gan ⁵ , Stephanie Lessig ⁶ , James Brewer ⁶ , Howard Feldman ⁶ , Charlotte Teunissen ⁷ , Adam Boxer ¹ ¹ UCSF Memory and Aging Center - San Francisco (United States), ² Amsterdam UMC - Amsterdam (Netherlands), ³ Denali Therapeutics - San Francisco (United States), ⁴ Harvard Medical School - Boston (United States), ⁵ Weill Cornell Medical College - New York (United States), ⁶ UC San Diego - San Diego (United States), ⁷ Amsterdam UMC - Amsterdam (United States)
	P042: Early experience with home administration of subcutaneous gantenerumab by study partner (non-professional care partner) in the GRADUATION study <u>Richard Perry</u> ¹ , Frank Boess ² , Marzia Scelsi ³ , Timo Grimmer ⁴ , Rafael Arroyo ⁵ , Christopher Lane ³ , Claire Lansdall ² , Janice Smith ³ ¹ Imperial College London - London (United Kingdom), ² F. Hoffmann-La Roche Ltd - Basel (Switzerland), ³ Roche Products Ltd - Welwyn Garden City (United Kingdom), ⁴ Klinikum rechts der Isar, Technical University of Munich - Munich (Germany), ⁵ Quirónsalud Madrid University Hospital - Madrid (Spain)
	P043: A Phase 1b study to evaluate the safety, tolerability and pharmacodynamics of PRI-002 in MCI and mild AD <u>Oliver Peters</u> ¹ , Nicoleta-Carmen Cosma ¹ , Janine Kutzsche ¹ , Dieter Willbold ¹ ¹ Charité – Berlin (Germany)
	P044: Enabling subcutaneous dosing of gantenerumab in Alzheimer's Disease <u>Beate Bittner</u> ¹ , Dietmar Schwab ¹ , Agnes Portron ¹ , Dominik Lott ¹ , Frank Boess ¹ , Rémy Kohler ¹ , Jakub Wojtowicz ¹ , Carsten Hofmann ¹ ¹ F. Hoffmann-La Roche Ltd - Basel (Switzerland)
	P045: The Internet-Based Conversational Engagement Clinical Trial (I-CONNECT) in Socially Isolated Adults 75+ Years Old: Primary Analyses Results <u>Hiroko Dodge</u> ¹ , Patrick Pruitt ¹ , Kexin Yu ¹ , Chao-Yi Wu ¹ , Jeffrey Kaye ¹ , Lisa Silbert ¹ , I-Conect Conect-Team ¹ ¹ Oregon Health & Science University - Portland (United States)
	P046: Computerized Games versus Crosswords Training in Mild Cognitive Impairment <u>Davangere Devanand</u> ¹ , Terry Goldberg ¹ , Min Qian ¹ , Murali Doraiswamy ² ¹ Columbia University Medical Center - New York (United States), ² Duke University - Durham (United States)
	P047: Pimavanserin and cardiovascular/electrocardiogram safety in patients with Alzheimer's disease <u>Pierre Tariot</u> ¹ , Victor Abler ² , Sanjeev Pathak ² , Bruce Coate ² , Mary Ellen Turner ²



	¹ Banner Alzheimer's Institute and University of Arizona College of Medicine - Phoenix, Az (United States), ² Acadia Pharmaceuticals Inc. - San Diego, Ca (United States)
	P048: The effects of the novel phosphodiesterase 9 (PDE9) inhibitor E2027 (irsenontrine) on CSF cGMP, additional CSF and plasma biomarkers, and clinical outcomes in amyloid positive and amyloid negative patients with Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD) Pallavi Sachdev ¹ , Kate Pinner ² , Theresa Devins ¹ , Larisa Reyderman ¹ , David Li ¹ , Shobha Dhadda ¹ , Lynn Kramer ¹ , Akihiko Koyama ¹ , Michael Irizarry ¹ , <u>Steven Hersch</u> ¹ ¹ Eisai Inc. - Nutley (United States), ² Eisai Ltd. - Hattfield (United Kingdom)
	P049: Clinical Activity of the p38α kinase inhibitor neflamapimod on verbal list learning may be tau pathology dependent in dementia with Lewy bodies (DLB) <u>John Alam</u> ¹ , Jennifer Conway ¹ , Hui-May Chu ² , Kelly Blackburn ¹ ¹ EIP Pharma, Inc - Boston (United States), ² Anoixis Corporation - Natick (United States)

Theme: Beyond Amyloid and Tau: Emerging Solutions

	P050: Molecules of senescent glial cells differentiate Alzheimer's disease from aging <u>Linbin Dai</u> ¹ , Feng Gao ¹ , Xinyi Lv ¹ , Zhaozhao Chen ¹ , Henrik Zetterberg ² , Kaj Blennow ² , Allan I Levey ³ , Qiqiang Tang ¹ , Jiong Shi ⁴ , Yong Shen ¹ ¹ University Of Science And Technology Of China - Hefei (China), ² University Of Gothenburg - Mölndal (Sweden), ³ Emory University - Atlanta (United States), ⁴ Capital Medical University - Beijing (China)
	P051: Improvement of cognitive dysfunction following repeated infusion of adipose tissue-derived stem cells <u>Kazuo Shigematu</u> ¹ , Mitsuko Ideno ² , Noyuki Komori ³ , Hisakazu Yamagishi ⁴ ¹ Minami Kyoto Hospital - Joyo (Japan), ² Takara Bio Inc. - Kyoto (Japan), ³ Nagitsuji Hospital - Kyoto (Japan), ⁴ Kyoto Prefectural University Of Medicine - Kyoto (Japan)
	P052: Novel application of deep canonical correlation analysis identifies regional brain atrophy linked to proinflammatory gut microbial genera before cognitive decline <u>Margo Heston</u> ^{1,2} , Zihang Meng ³ , Akshay Kohli ^{1,2} , Antonio González ⁴ , Sterling Johnson ^{1,2,5} , Rob Knight ^{4,6,7,8} , Rima Kaddurah-Daouk ^{9,10,11,12} , Federico Rey ¹³ , Vikas Singh ^{3,14,15} , Barbara Bendlin ^{1,2,5} ¹ Wisconsin Alzheimer's Disease Research Center - Madison (United States), ² Division of Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health - Madison (United States), ³ Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison - Madison (United States), ⁴ Department of Pediatrics, University of California, San Diego - La Jolla (United States), ⁵ Wisconsin Alzheimer's Institute - Madison (United States), ⁶ Department of Bioengineering, University of California, San Diego - La Jolla (United States), ⁷ Department of Computer Science & Engineering, University of California, San Diego - La Jolla (United States), ⁸ Center for Microbiome Innovation, University of California, San Diego - La Jolla (United States), ⁹ Department of Psychiatry and Behavioral Sciences, Duke University - Durham (United States), ¹⁰ Department of Medicine, Duke University - Durham (United States), ¹¹ Duke Institute of Brain Sciences, Duke University - Durham (United States), ¹² Duke University Medical Center - Durham (United States), ¹³ Department of Bacteriology, University of Wisconsin- - Madison (United States), ¹⁴ Department of Computer Sciences, University of Wisconsin-Madison - Madison (United States), ¹⁵ Department of Statistics, University of Wisconsin-Madison - Madison (United States)
	P053: Beyond targeting Ab and tau: Novel formulations of alpha-cyclodextrins for the safe (not ototoxic) and convenient (oral) Prevention and Treatment of Alzheimer's Disease




	<p><u>Knut Wittkowski</u>¹ ¹<i>Asdera Llc - New York (United States)</i></p>
	<p>P054: Lomcel-B as a Geroscience Therapeutic Candidate for Dementia and Frailty <u>Anthony Oliva</u>¹, Kevin Ramdas¹, Lisa McClain-Moss¹, Dan Gincel¹, Danial Mehranfard¹, K. Chris Min¹, Joshua Hare¹ ¹<i>Longeveron Inc. - Miami (United States)</i></p>
	<p>P055: Community Based Options to Screen for Clinical Trial Eligibility: Experience and data from the African American Fighting Alzheimer's in Mid-Life (AA-FAIM) Study <u>Carey E. Gleason</u>^{1,2}, Dorothy Farrar Edwards^{1,3}, Diane C. Gooding⁴, Gina Green Harris^{5,6}, Nathaniel A. Chin^{1,2}, Cynthia M. Carlsson^{1,7}, Maria Mora Pinzon^{7,1}, Melissa F. Metoxen⁸, Shenikqua Bouges^{1,9}, Fabu P. Carter^{1,2}, Megan Zuelsdorff^{10,2}, Rebecca Langhough Koscik⁷, Hector Salazar¹, Nia C. Norris^{7,5}, Derek L. Norton¹¹ ¹<i>Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine and Public Health - Madison (United States)</i>, ²<i>Wisconsin Alzheimer's Disease Research Center - Madison (United States)</i>, ³<i>Wisconsin Alzheimer's Disease Research Center - Madison (United States)</i>, ⁴<i>Department of Psychology, University of Wisconsin - Madison (United States)</i>, ⁵<i>Center for Community Engagement and Health Partnerships - Milwaukee (United States)</i>, ⁶<i>Center for Health Disparities Research, University of Wisconsin School of Medicine and Public Health - Madison (United States)</i>, ⁷<i>Wisconsin Alzheimer's Institute, University of Wisconsin School of Medicine and Public Health - Madison (United States)</i>, ⁸<i>Native American Center for Health Professions, University of Wisconsin School of Medicine and Public Health - Madison (United States)</i>, ⁹<i>Madison VA GRECC, William S. Middleton Memorial Hospital - Madison (United States)</i>, ¹⁰<i>School of Nursing, University of Wisconsin - Madison (United States)</i>, ¹¹<i>Department of Biostatistics and Medical Informatics University of Wisconsin - Madison (United States)</i></p>
	<p>P056: The Gut-PRO Study: A Pilot Probiotic Intervention Study in Alzheimer's Disease <u>Jea Woo Kang</u>¹, Sandra J. Harding¹, Margo Heston¹, Alfred Eiji s Braceros¹, Nancy Davenport-Sis¹, Nathaniel Chin¹, Henrik Zetterberg², Federico Rey¹, Barbara b Bendlin¹ ¹<i>University of Wisconsin-Madison - Madison (United States)</i>, ²<i>University of Gothenburg, Sahlgrenska University Hospital - Mölndal (Sweden)</i></p>
	<p>P057: Lifestyle therapeutics to promote healthy brain aging and AD risk reduction: current and future research directions and implementation Kirk Erickson¹, Alvaro Pascual-Leone², <u>Tina Smith</u>³, Paul Bendheim⁴ ¹<i>University of Pittsburgh - Pittsburgh (United States)</i>, ²<i>Harvard University - Boston (United States)</i>, ³<i>WellMed Charitable Foundation - San Antonio (United States)</i>, ⁴<i>University of Arizona; BrainSavers Inc. - Phoenix (United States)</i></p>
	<p>P058: Blood levels of memory CD8 T cells that induce AD-like pathology in mice correlate with cognition and decreased CSF Abeta42 and increased CSF Tau, and accurately track AD in human patients <u>Christopher Wheeler</u>¹, Van Dam Debby², Vermeiren Yannick², De Reu Hans², De Deyn Peter Paul³ ¹<i>T-Neuro Pharma - Aptos (United States)</i>, ²<i>University of Antwerp - Antwerp (Belgium)</i>, ³<i>University of Groningen - Groningen (Netherlands)</i></p>
	<p>P059: Effects of non-invasive brain stimulation on individual alpha power <u>Oezguer A. Onur</u>¹, Ronja Fassbender¹ ¹<i>Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany - Cologne (Germany)</i></p>
	<p>P060: A pragmatic assessment of ultra-fast MRI in real-life clinical and research cognitive practice <u>Miguel Rosa-Grilo</u>¹, Eoin Mulroy¹, Millie Beament¹, Haroon Chughtai², Dave Thomas¹, Geoff</p>

	<p>Parker ², Nick Fox ¹, Catherine Mummery ¹ ¹<i>UK Dementia Research Centre at University College London (UCL) - London (United Kingdom)</i>, ²<i>Centre for Medical Image Computing, Department of Medical Physics & Biomedical Engineering and Department of Neuroinflammation at University College London (UCL) - London (United Kingdom)</i></p>
	<p>P061: Optimal conditions for entraining gamma waves using sensory stimulation in older adults <u>Yeseung Park</u> ¹, Euisuk Yoon ¹, Ki Woong Kim ¹ ¹<i>Seoul National University - Seoul (Korea, Republic of)</i></p>
	<p>P062: Serum levels of glycan epitope correlate with tau and predict progression to dementia in combination with APOE4 allele status <u>Robin Ziyue Zhou</u> ¹, Davide Liborio Vetrano ², Giulia Grande ², Bengt Winblad ¹, Lars Tjernberg ¹, Sophia Schedin-Weiss ¹ ¹<i>Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet - Solna (Sweden)</i>, ²<i>Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University - Stockholm (Sweden)</i></p>
	<p>P063: Serum proBDNF predicts memory gains after lifestyle changes in elderly persons - A subgroup analysis among adherent participants in the FINGER study <u>Anna Matton</u> ¹, Krister Håkansson ¹, Julen Goicolea ¹, Makrina Daniilidou ¹, Tiia Ngandu ², Gorka Gerenu ¹, Alina Solomon ³, Hilikka Soininen ³, Tiina Laatikainen ², Miia Kivipelto ¹ ¹<i>Karolinska Institutet - Solna (Sweden)</i>, ²<i>Finnish Institute on Health and Welfare - Helsinki (Finland)</i>, ³<i>University of Eastern Finland - Kuopio (Finland)</i></p>
	<p>P064: Evaluation of long-term safety and compliance to a multinutrient intervention for up to 8 years in mild cognitive impairment / prodromal Alzheimer's disease: data from the randomised controlled LipiDiDiet trial <u>Tobias Hartmann</u> ^{1,2}, Alina Solomon ^{3,4,5}, Pieter Visser ^{6,7}, Kai Blennow ^{8,9}, Miia Kivipelto ^{10,11,5}, Hilikka Soininen ^{12,10} ¹<i>Deutsches Institut für Demenzprävention, Saarland University - Homburg (Germany)</i>, ²<i>Experimental Neurology - Homburg (Germany)</i>, ³<i>Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland)</i>, ⁴<i>Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden)</i>, ⁵<i>Clinical Trials Unit, Theme Aging, Karolinska University Hospital - Huddinge (Sweden)</i>, ⁶<i>Department of Neurology, Alzheimer Center, VU University Medical Center - Amsterdam (Netherlands)</i>, ⁷<i>Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht - Maastricht (Netherlands)</i>, ⁸<i>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg - Mölndal (Sweden)</i>, ⁹<i>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, - Mölndal (Sweden)</i>, ¹⁰<i>Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland - Kuopio (Finland)</i>, ¹¹<i>Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institute - Stockholm (Sweden)</i>, ¹²<i>Neurocenter, Department of Neurology, Kuopio University Hospital - Kuopio (Finland)</i></p>
	<p>P065: Method for the detection of Alzheimer's disease-specific proteins in nasal secretion <u>Timo Grimmer</u> ¹, Hilary Wunderlich ², Marion San Nicoló ², Patrick Sommer ¹, Oliver Goldhardt ¹, Arno Schaepe ², Klaus Hallermayer ², Harald Waltenberger ³, Sabine Mertzig ², Thomas Heydler ², Mareike Haack ² ¹<i>Technical University of Munich, School of Medicine, Klinikum rechts der Isar - Munich (Germany)</i>, ²<i>Noselab GmbH - Munich (Germany)</i>, ³<i>Microcoat Biotechnologie GmbH - Munich (Germany)</i></p>
	<p>P066: Clinical utility of non-invasive whole transcriptomic profiling of Alzheimer's disease Shusuke Toden ¹, Jiali Zhuang ¹, Stephen Quake ², Robert Rissman ³, James Brewer ³, <u>John Sninsky</u> ¹</p>

	¹ Molecular Stethoscope - South San Francisco (United States), ² Stanford University - Stanford (United States), ³ University of California, San Diego - San Diego (United States)
	P067: Development of a selective estrogen β-receptor phytoestrogen formulation – PhytoSERM – for improving cognitive health to reduce Alzheimer’s risk and menopausal symptoms: A Phase 2 randomized clinical trial Claudia Lopez ¹ , Mark Drew ¹ , <u>Gerson Hernandez</u> ¹ , Roberta Brinton ¹ ¹ University of Arizona - Tucson (United States)
	P068: Determinants of Individual Differences in the Efficacy of Aerobic Exercise to Improve Brain Health and Reduce Alzheimer’s Disease Risk in Older African Americans Mark Gluck ¹ , <u>Bernadette Fausto</u> ¹ ¹ Rutgers University-Newark - Newark, Nj (United States)

Posters presented on Thursday, December 1st from 8am to 6pm







Theme: Clinical Trials Imaging


	P069: Do the radiomics or structural and functional magnetic resonance imaging give additional information to predict brain amyloid positivity? <u>Yoojin Lee</u> ¹ , Sungyang Jo ¹ , Jae-Hong Lee ¹ ¹ Asan Medical Center - Seoul (Korea, Republic of)
	P070: Differential effects of cardiometabolic syndrome on brain age in relation to sex and ethnicity <u>Sung Hoon Kang</u> ¹ , Mengting Liu ² , Sang Won Seo ³ , Hosung Kim ² ¹ Department Of Neurology, Korea University Guro Hospital, Korea University College Of Medicine - Seoul (Korea, Republic of), ² Usc Steven Neuroimaging And Informatics Institute, Keck School Of Medicine Of University Of Southern California - Los Angeles (United States), ³ Departments Of Neurology, Samsung Medical Center, Sungkyunkwan University School Of Medicine - Seoul (Korea, Republic of)
	P071: Genome-Wide Association Study of the functional brain network for Alzheimer’s Disease <u>Minji Kim</u> ¹ , Jong-Min Lee ² ¹ Department Of Electronic Engineering, Hanyang University - Seoul (Korea, Republic of), ² Department Of Biomedical Engineering, Hanyang University - Seoul (Korea, Republic of)
	P072: Cerebral small vessel disease burden predicts neurodegeneration and clinical progression in nondemented elderly Jin-Tai Yu ¹ , <u>Lan Tan</u> ² ¹ Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University, Shanghai, China. - Shanghai (China), ² Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China - Qingdao (China)
	P073: Association of regional amyloid burden and brain volume with cognitive performances among individuals with subjective cognitive decline <u>Chonghwee Lee</u> ¹ , Dong Won Yang ¹ , Yun Jeong Hong ² , Seonghee Ho ³ , Jee Hyang Jeong ⁴ , Kee Hyung Park ⁵ , Sangyun Kim ⁶ , Min Jeong Wang ⁷ , Seong Hye Choi ⁸ , Sanggyu Lee ⁹ ¹ Neurology, Catholic University Of Korea, Seoul St. Mary's Hospital - Seoul (Korea, Republic of), ² Neurology, Catholic University Of Korea, Seoul St. Mary's Hospital - Uijeongbu (Korea, Republic of), ³ Neurology, Changwon Hanmaeum Hospital - Changwon (Korea, Republic of), ⁴ Neurology, Womans






	<p>University School Of Medicine, Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of), ⁵Neurology, Gachon University Gil Hospital - Incheon (Korea, Republic of), ⁶Neurology, Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of), ⁷Neurology, Roa Clinic - Seongnam (Korea, Republic of), ⁸Neurology, Inha University School Of Medicine, Inha University Hospital - Incheon (Korea, Republic of), ⁹Neolab Convergence Inc. - Seoul (Korea, Republic of)</p>
	<p>P074: The role of subthreshold levels of amyloid deposition on dementia conversion-validated with ADNI <u>Hyung-Ji Kim</u>¹, Jae-Hong Lee² ¹Uijeongbu Eulji Medical Center - Uijeongbu-Si (Korea, Republic of), ²Asan Medical Center - Seoul (Korea, Republic of)</p>
	<p>P075: Evaluation of a clinically validated digital platform to provide Diffusion MRI biomarkers in Alzheimer's disease Etienne Bories¹, Arthur Bezie¹, Didier Cassereau¹, Julie Rachline¹, Iyed Trimeche¹, Jean-Baptiste Martini¹, <u>Vincent Perlbarg</u>¹ ¹BRAINTALE SAS - Strasbourg (France)</p>
	<p>P076: Increase in white matter volume and myelination after 6 months of 40Hz gamma sensory stimulation therapy in patients on Alzheimer's Disease spectrum <u>Xiao Da</u>¹, Evan Hempel¹, Holly Mrozak¹, Zach Malchano¹, Brent Vaughan¹, J. Thomas Megerian¹, Mihaly Hajos^{1,2}, Aylin Cimenser¹ ¹Cognito Therapeutics - Cambridge, Ma (United States), ²Yale University School of Medicine - New Haven, Ct (United States)</p>
	<p>P077: Summary of ACR Phantom MRI site qualification findings over 7 years and recommendations moving forward <u>Luc Bracoud</u>¹, Joonmi Oh², Qui Cao², Chris Conklin³, Madhura Ingalthalikar³, Ha Pham², David Scott², Joyce Suh² ¹Clario (formerly Bioclinica) - Lyon (France), ²Clario (formerly Bioclinica) - San Mateo (United States), ³Clario (formerly Bioclinica) - Princeton (United States)</p>
	<p>P078: Amyloid-based disease models for clinical endpoint prediction in Alzheimer's disease Luis Peraza¹, Richard Joules¹, <u>Robin Wolz</u>¹ ¹IXICO - London (United Kingdom)</p>
	<p>P079: Effects of Alzheimer and Lewy Body Disease Pathologies on Brain Metabolism Byong Seok Ye¹, <u>Sungwoo Kang</u>² ¹MD. PhD - Seoul (Korea, Republic of), ²MD - Seoul (Korea, Republic of)</p>
	<p>P080: Title: REducing Sleep Apnoea for the PrEvention of Dementia (RESHAPED): The protocol of a multi-site feasibility randomised controlled trial <u>Sharon Naismith</u>¹, Camilla Hoyos¹, Craig Phillips¹, Yaffe Kristine², Ralph Martins³, Nathaniel Marshall¹, Jim Lagopoulos⁴, Melinda Jackson⁵, Loren Mowszowski¹, Ronald Grunstein¹ ¹University of Sydney - Sydney (Australia), ²University of California - San Francisco (United States), ³University of Macquarie - Sydney (Australia), ⁴University of Sunshine Coast - Sunshine Coast (Australia), ⁵Monash University - Melbourne (Australia)</p>
	<p>P081: Arterial stiffness is associated with cortical tau burden <u>Young Noh</u>¹ ¹Gachon University Gil Medical Center - Incheon (Korea, Republic of)</p>
	<p>P082: Application of fully automatic Hippocampal sub-field segmentation volumes to standard resolution T1 MR Imaging in Alzheimer's disease</p>






	Richard Joules ¹ , <u>Robin Wolz</u> ¹ ¹ <i>IXICO - London (United Kingdom)</i>
	P083: Long-term progression of amyloid (A) and tau (T) image-based biomarker in Alzheimer's disease spectrum <u>Han-Kyeol Kim</u> ¹ , Hanna Cho ¹ , Jae Hoon Lee ² , Young Hoon Ryu ² , Chul Hyung Lyoo ¹ ¹ <i>Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of)</i> , ² <i>Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of)</i>
	P084: Independent effects of hippocampal subfield volumes and p-tau on memory performance in clinically unimpaired older adults <u>Tammy Tran</u> ¹ , Alexandra Trelle ¹ , Wilson Edward ¹ , Gayle Deutsch ¹ , Sharon Sha ¹ , Katrin Andreasson ¹ , Valerie Carr ¹ , Geoffrey Kerchner ¹ , Elizabeth Mormino ¹ , Anthony Wagner ¹ ¹ <i>Stanford University - Stanford (United States)</i>
	P085: Supporting the Communication of Modern Alzheimer's Data through Augmented Reality and Web Technologies <u>Tyler Ard</u> ¹ , Bienkowski Michael ¹ , Arthur Toga ¹ ¹ <i>USC Stevens Neuroimaging and Informatics Institute - Los Angeles (United States)</i>
	P086: Longitudinal assessment of novel imaging markers of neuroinflammation, axonal density and demyelination as biomarkers in Alzheimer's Disease <u>Maggie Roy</u> ¹ , Matthieu Dumont ¹ , Jean-Christophe Houde ¹ , Maxime Descoteaux ¹ ¹ <i>Imeka - Sherbrooke (Canada)</i>
	P087: Predicting PET-determined ATN biomarker status in Alzheimer's disease with MRI using deep convolutional neural networks <u>Christopher Lew</u> ¹ , Longfei Zhou ¹ , Maciej Mazurowski ¹ , P Murali Doraiswamy ¹ , Susan Landau ² , Jeffrey Petrella ³ ¹ <i>Duke University Medical Center - Durham (United States)</i> , ² <i>University of California, Berkeley - Berkeley (United States)</i> , ³ <i>Duke University Medical Center - Durham (United States)</i>
	P088: Early [18F]-PI-2620 tau PET signal in the stages preceding AD dementia <u>Christina Young</u> ¹ , Hillary Vossler ¹ , Edward Wilson ¹ , Alexandra Trelle ² , Kathleen Poston ¹ , Michael Zeineh ¹ , Michael Greicius ¹ , Greg Zaharchuk ¹ , Victor Henderson ¹ , Anthony Wagner ² , Katrin Andreasson ¹ , Guido Davidzon ¹ , Elizabeth Mormino ¹ ¹ <i>Stanford ADRC - Stanford (United States)</i> , ² <i>Stanford Department of Psychology - Stanford (United States)</i>
	P089: Amyloid and tau burden in an at-risk, cognitively unimpaired clinical trial cohort: Neuroimaging data from the U.S. POINTER trial <u>Alice Murphy</u> ¹ , Theresa Harrison ¹ , Tyler Ward ¹ , Prashanthi Vemuri ² , Robert Koeppel ³ , Samuel Lockhart ⁴ , Mark Espeland ⁴ , Danielle Harvey ⁵ , Joseph Masdeu ⁶ , Hwamee Oh ⁷ , Darren Gitelman ⁸ , Neelum Aggarwal ⁹ , Laura Baker ⁴ , Charles Decarli ⁵ , Susan Landau ¹ ¹ <i>U.C. Berkeley (United States)</i> , ² <i>Mayo Clinic (United States)</i> , ³ <i>University of Michigan (United States)</i> , ⁴ <i>Wake Forest School of Medicine (United States)</i> , ⁵ <i>U.C. Davis (United States)</i> , ⁶ <i>Houston Methodist (United States)</i> , ⁷ <i>Brown University (United States)</i> , ⁸ <i>Advocate Lutheran General Hospital (United States)</i> , ⁹ <i>Rush University Medical Center (United States)</i>









Theme: Clinical Trials: biomarkers including plasma






	<p>P090: Impacts of amyloid burden on longitudinal cognitive declines in subjective cognitive decline: a prospective cohort study</p> <p><u>Yun Jeong Hong</u>¹, Dong Won Yang², Seonghee Ho², Kwonoh Park³, Jee Hyang Jeong⁴, Kee Hyung Park⁵, Sangyun Kim⁶, Min Jeong Wang⁶, Seong Hye Choi⁷, Sanggyu Lee⁸</p> <p>¹<i>Uijeongbu St. Mary's Hospital - Uijeongbu (Korea, Republic of)</i>, ²<i>Seoul St. Mary's Hospital - Seoul (Korea, Republic of)</i>, ³<i>Pusan National University Yangsan Hospital - Yangsan (Korea, Republic of)</i>, ⁴<i>Ewha Womans University Seoul Hospital - Seoul (Korea, Republic of)</i>, ⁵<i>Gachon University Gil Hospital - Incheon (Korea, Republic of)</i>, ⁶<i>Seoul National University College Of Medicine, Seoul National University Bundang Hospital - Seongnam (Korea, Republic of)</i>, ⁷<i>Inha University School Of Medicine - Incheon (Korea, Republic of)</i>, ⁸<i>Neolab Convergence Inc. - Seoul (Korea, Republic of)</i></p>
	<p>P091: Predictive value of plasma p-tau181 versus baseline amyloid-PET for longitudinal amyloid accumulation in asymptomatic Alzheimer's Disease</p> <p><u>Rik Vandenberghe</u>¹, Steffi De Meyer¹, Emma Lockett¹, Jeroen Vanbrabant², Jolien Schaefferbeke¹, Mariska Reinartz¹, Isabelle Cleynen³, Erik Stoops², Eugene Vanmechelen², Koen Van Laere⁴</p> <p>¹<i>Alzheimer Research Centre Ku Leuven, Leuven Brain Institute - Leuven (Belgium)</i>, ²<i>Adx Neurosciences - Zwijnaarde (Belgium)</i>, ³<i>Laboratory For Complex Genetics - Leuven (Belgium)</i>, ⁴<i>Nuclear Medicine Service, University Hospitals Leuven - Leuven (Belgium)</i></p>
	<p>P092: Blood biomarkers for Alzheimer's disease to predict dementia risk in a large clinic-based cohort: implications for clinical trials</p> <p><u>Vincent Planche</u>¹, Vincent Bouteloup¹, Geneviève Chêne¹, Carole Dufouil¹</p> <p>¹<i>Bordeaux University - Bordeaux (France)</i></p>
	<p>P093: Independent Effect of Body Mass Index Variation on Amyloid-β Positivity</p> <p><u>Sung Hoon Kang</u>¹, Jong Hyuk Kim², Kyunga Kim², Sang Won Seo³</p> <p>¹<i>Department Of Neurology, Korea University Guro Hospital, Korea University College Of Medicine - Seoul (Korea, Republic of)</i>, ²<i>Department Of Digital Health, Saihst, Sungkyunkwan University - Seoul (Korea, Republic of)</i>, ³<i>Department Of Neurology, Samsung Medical Center, Sungkyunkwan University School Of Medicine - Seoul (Korea, Republic of)</i></p>
	<p>P094: Phase 2 study reveals an adequate PK/PD relationship of bosutinib in Dementia with Lewy Bodies and clears the path for larger Phase 2/3 investigations</p> <p><u>Charbel Moussa</u>¹, Fernando Pagan², Torres-Yaghi Yasar², Hebron Michaleine¹, Turner Raymond S¹, Ahn Jaeil¹</p> <p>¹<i>Georgetown University Medical Center - Washington (United States)</i>, ²<i>Medstar Georgetown Hospital - Washington (United States)</i></p>
	<p>P095: Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias</p> <p><u>Jonathan Haroon</u>¹, Kennedy Mahdavi^{1,2}, Kaya Jordan¹, Elisabeth Rindner¹, Margaret Zielinski¹, Victoria Venkatraman^{1,2}, Dayan Goodenowe³, Kaitlyn Hofmeister³, Clarence Ahlem⁴, Christopher Reading⁴, Joseph Palumbo⁴, Bijan Pourat⁵, Sheldon Jordan^{1,2}</p> <p>¹<i>The Regenesys Project - Santa Monica (United States)</i>, ²<i>Synaptec Network - Santa Monica (United States)</i>, ³<i>Prodrome Sciences USA LLC - Temecula (United States)</i>, ⁴<i>Biovie Inc. - Carson City (United States)</i>, ⁵<i>Pourat MD - Beverly Hills (United States)</i></p>
	<p>P096: Robustness of cerebrospinal fluid (CSF) amyloid-β 1–42/amyloid-β 1–40 (Aβ42/Aβ40) and phosphorylated tau/amyloid-β 1–42 (pTau/Aβ42) biomarker ratios in classification of amyloid positron emission tomography (PET) positivity in routine clinical use</p> <p><u>Chad Logan</u>¹, Henrik Schinke¹, Christina Rabe², Maryline Simon³, Oskar Hansson^{4,5}, Kaj Blennow^{6,7}, Erik Stomrud^{4,5}</p>

	<p>¹Roche Diagnostics Gmbh - Penzberg (Germany), ²Genentech, Inc., - South San Francisco (United States), ³Roche Diagnostics International Ltd - Rotkreuz (Switzerland), ⁴Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), ⁵Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁶Department Of Psychiatry And Neurochemistry, Institute Of Neuroscience And Physiology, The Sahlgrenska Academy At The University Of Gothenburg - Mölndal (Sweden), ⁷Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden)</p>
	<p>P097: the biomarker-based etiological diagnosis of neurocognitive disorders: the European Inter-Societal Delphi Consensus <u>Stefania Orini</u> ^{1,2}, Cristina Festari ³, Federico Massa ⁴, Matteo Cotta Ramosino ^{5,6}, Flavio Nobili ^{7,8}, Giovanni Battista Frisoni ^{9,10} The European Inter-Societal Consensus On The Biomarker-Based Diagnosis Of Dement ¹¹ ¹Alzheimer's Unit-Memory Clinic, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli - Brescia, (Italy), ²Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, - Brescia (Italy), ³Laboratory Of Alzheimer's Neuroimaging And Epidemiology, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, - Brescia, (Italy), ⁴Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dinogmi), University Of Genoa - Genoa (Italy), ⁵Unit Of Behavioral Neurology, Irccs Mondino Foundation, - Pavia (Italy), ⁶Department of Brain and Behavioral Sciences, University of Pavia, - Pavia, (Italy), ⁷Department Of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal And Child Health (dinogmi), University Of Genoa, - Genoa (Italy), ⁸IRCCS Ospedale Policlinico San Martino, - Genoa (Italy), ⁹Laboratory Of Neuroimaging Of Aging (lanvie), University Of Geneva, - Geneva (Switzerland), ¹⁰Geneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, G - Geneva (Switzerland), ¹¹The European Inter-Societal Consensus On The Biomarker-Based Diagnosis Of Dementia</p>
	<p>P098: A candidate microRNA profile for early diagnosis of sporadic Alzheimer's disease <u>Maria Tsamou</u> ¹, Eva Ntanasi ², Faidra Kalligerou ², Nicolaos Scarmeas ², Susanna Skalicky ³, Matthias Hackl ³, Erwin L Roggen ¹ ¹Toxgensolutions - Maastricht (Netherlands), ²1st Department Of Neurology, Aiginition Hospital, National And Kapodistrian University Of Athens Medical School - Athens (Greece), ³Tamirna - Wien (Austria)</p>
	<p>P099: Data-driven 18F-Flortaucipirt cut-offs for preclinical and early AD <u>Giulia Quattrini</u> ^{1,2}, Clarissa Ferrari ³, Michela Pievani ¹, Federica Ribaldi ⁴, Szymon Tomczyk ⁴, Giovanni Battista Frisoni ⁴, Valentina Garibotto ⁴, Moira Marizzoni ¹ ¹Laboratory Of Alzheimer's Neuroimaging And Epidemiology (lane), Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy), ²Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy - Brescia (Italy), ³Unit Of Statistics, Irccs Istituto Centro San Giovanni Di Dio Fatebenefratelli, Brescia, Italy - Brescia (Italy), ⁴Memory Clinic And Lanvie-Laboratory Of Neuroimaging Of Aging, University Hospitals And University Of Geneva, Geneva, Switzerland - Geneva (Switzerland)</p>
	<p>P100: Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimer's Disease and Neurodegeneration stratified by sex <u>Irene Cumplido Mayoral</u> ^{1,2}, Marta Milà-Alomà ^{1,2,3,4}, Luigi Lorenzini ⁵, Alle Meije Wink ⁵, Henk J.m.m. Mutsaerts ⁵, Sven Haller ⁶, Gael Chetelat ⁷, Frederik Barkhof ^{5,8}, Margherita Carboni ⁹, Gwendlyn Kollmorgen ¹⁰, Henrik Zetterberg ^{11,12,13,14}, Kaj Blennow ^{11,12}, Marc Suárez-Calvet ^{1,3,4,15}, Verónica Vilaplana ¹⁶, Juan Domingo Gispert ^{1,3,17}</p>







	<p>¹Barcelonaβeta Brain Research Center (bbrc), Pasqual Maragall Foundation - Barcelona (Spain), ²Universitat Pompeu Fabra - Barcelona (Spain), ³IMIM (Hospital del Mar Medical Research Institute) - Barcelona (Spain), ⁴CIBER Fragilidad y Envejecimiento Saludable (CIBERFES) - Madrid (Spain), ⁵Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC - Amsterdam (Netherlands), ⁶CIRD Centre d'Imagerie Rive Droite - Geneva (Switzerland), ⁷Imaging of Neurological Disorders", Institut Blood and Brain @ Caen - Normandie, Cyceron - Caen (France), ⁸Institutes of Neurology and Healthcare Engineering, University College London - London (United Kingdom), ⁹Roche Diagnostics International Ltd - Rotkreuz Zg (Switzerland), ¹⁰Roche Diagnostics GmbH - Penzberg (Germany), ¹¹Institute of Neuroscience and Physiology, University of Gothenburg - Mölndal (Sweden), ¹²Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - Mölndal (Sweden), ¹³Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology - London (United Kingdom), ¹⁴UK Dementia Research Institute at UCL - London (United Kingdom), ¹⁵Servei de Neurologia, Hospital del Mar - Barcelona (Spain), ¹⁶Department of Signal Theory and Communications, Universitat Politècnica de Catalunya - Barcelona (Spain), ¹⁷Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) - Madrid (Spain)</p>
	<p>P101: Cerebrospinal fluid placental growth factor in relation to cerebrovascular disease and diabetes in non-demented elderly <u>Eske Christiane Gertje</u> ^{1,2}, Shorena Janelidze ¹, Danielle Van Westen ^{3,4}, Erik Stomrud ^{1,5}, Sebastian Palmqvist ^{1,5}, Oskar Hansson ^{1,5}, Niklas Mattsson-Carlgren ^{1,6,7} ¹Clinical Memory Research Unit, Department Of Clinical Sciences Malmö, Lund University - Malmö (Sweden), ²Department of Internal Medicine, Skåne University Hospital - Lund (Sweden), ³Diagnostic Radiology, Department Of Clinical Sciences Lund, Lund University - Lund (Sweden), ⁴Imaging and Function, Skåne University Hospital - Lund (Sweden), ⁵Memory Clinic, Skåne University Hospital - Malmö (Sweden), ⁶Department of Clinical Sciences Lund, Neurology, Lund University, Skåne University Hospital - Lund (Sweden), ⁷Wallenberg Center for Molecular Medicine, Lund University - Lund (Sweden)</p>
	<p>P102: Plasma AD biomarkers can Predict Hippocampal Atrophy <u>Hyung-Ji Kim</u> ¹, Jae-Hong Lee ² ¹Uijeongbu Eulji Medical Center - Uijeongbu-Si (Korea, Republic of), ²Asan Medical Center - Seoul (Korea, Republic of)</p>
	<p>P103: Assessment of Plasma p-tau181 in TANGO, a Phase 2 study of Gosuramemab in Patients with early Alzheimer's Disease <u>Julie Czerkowicz</u> ¹, Jessica Kong ¹, Annie Racine ¹, Carrie Rubel ¹, Jessica Collins ¹, Melanie Shulman ¹, Danielle Graham ¹, John Beaver ¹, Samantha Budd Haeberlein ¹ ¹Biogen - Cambridge (United States)</p>
	<p>P104: Corneal confocal microscopy and MRI brain volumetry: Prognostic biomarkers for progression from mild cognitive impairment to dementia <u>Georgios Ponirakis</u> ¹, Rayaz Malik ¹ ¹Weill Cornell Medicine in Qatar - Doha (Qatar)</p>
	<p>P105: Oligomer biomarkers for preclinical and clinical drug development in neurodegenerative disorders Oliver Bannach ^{1,2}, Lara Blömeke ^{1,2}, Bettina Kass ¹, Alice Chen-Plotkin ³, Oliver Peters ⁴, <u>Dieter Willbold</u> ^{1,5} ¹Forschungszentrum Jülich - Jülich (Germany), ²atlyoid GmbH - Düsseldorf (Germany), ³University of Pennsylvania - Philadelphia (United States), ⁴Charité Universitätsmedizin Berlin - Berlin (Germany), ⁵Heinrich-Heine-Universität Düsseldorf - Düsseldorf (Germany)</p>









	<p>P106: Exploratory study on the proteomic and transcriptomic content of plasma extracellular vesicles in AD patients</p> <p><u>Maria Solaguren-Beascoa</u>¹, Ana Gámez-Valero^{1,2}, Ana M. Ortiz³, Carla Minguet³, Ricardo Gonzalo³, Georgia Escaramís^{1,2}, Montserrat Costa³, Eulàlia Martí^{1,2}</p> <p>¹Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Institut of Neurociències, Universitat de Barcelona - Barcelona (Spain), ²Centro de Investigación Biomédica en Red sobre Epidemiología y Salud Pública (CIBERESP) - Barcelona (Spain), ³Grifols Bioscience Research Group - Barcelona (Spain)</p>
	<p>P107: Towards the development and validation of a general-purpose regulatory-grade neuroimage analysis tool</p> <p><u>Nick Henscheid</u>¹, Ioannis Pappas², Ryan Cabeen², Jagdeep Podichetty¹, Samuel Hobel², Christopher Weber³, Yashmin Karten¹, Klaus Romero¹, Sudhir Sivakumaran¹, Arthur Toga²</p> <p>¹Critical Path Institute - Tucson (United States), ²University of Southern California - Los Angeles (United States), ³Alzheimer's Association - Chicago (United States)</p>
	<p>P108: Bio-Hermes: A Validation Study to Assess a Meaningful Relationship Between Blood and Digital Biomarkers with Aβ PET Scans for Alzheimer's Disease</p> <p>Jennifer Gaudioso¹, Sarah Hollingshead¹, John Dwyer¹, Jason Bork¹, Richard Mohs¹, Katy Smith¹, Diana Kerwin², <u>Douglas Beauregard</u>¹</p> <p>¹Global Alzheimer's Platform Foundation - Washington (United States), ²Kerwin Medical Center - Dallas (United States)</p>
	<p>P109: Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer's Disease</p> <p><u>Charisse N. Winston</u>¹, Oliver Lanford², Natalie Levin¹, Rema Raman², Kevin Yarasheski³, Tim West³, Sarah Abdel-Latif², Michael Donohue², Akinori Nakamura⁴, Kenji Toba⁵, Colin L. Masters⁶, James Doecke⁷, Reisa A. Sperling⁸, Paul S. Aisen⁹, Robert A. Rissman¹⁰</p> <p>¹Department of Neurosciences, University of California San Diego - La Jolla (United States), ²Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California - San Diego (United States), ³C2N Diagnostics - St. Louis (United States), ⁴Department of Biomarker Research, National Center for Geriatrics and Gerontology - Obu (Japan), ⁵National Center for Geriatrics and Gerontology, Obu, Aichi, Japan, and Tokyo Metropolitan Institute of Gerontology - Obu (Japan), ⁶The Florey Institute, The University of Melbourne - Parkville (Australia), ⁷the Commonwealth Scientific and Industrial Research Organization - Herston Qld (Australia), ⁸Harvard Medical School - Boston (United States), ⁹Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California - Los Angeles (United States), ¹⁰Department of Neurosciences, University of California San Diego and VA San Diego Healthcare System - La Jolla (United States)</p>
	<p>P110: Myocardial sympathetic denervation biomarkers for early detection of prodromal DLB</p> <p><u>Mee Young Park</u>¹, Dong Sung Shin¹</p> <p>¹Neurology Yeungnam University Medical Center - Daegu (Korea, Republic of)</p>
	<p>P111: pTau181 plasma biomarker performance as an inclusion criterion in the RETHINK-ALZ and REFOCUS-ALZ trials in mild-to-moderate Alzheimer's disease</p> <p><u>Anna Mammel</u>¹, Pankaj Kumar², Lindsay Burns³, Donald Biehl¹, Mary Encarnacion², Anna Cruz², Ging-Yuek Robin Hsiung⁴, Ian Mackenzie⁴, Veronica Hirsch-Reinshagen⁴, Ali Mousavi², Ryan Fortna^{1,5}, James Kupiec³, Hans Frykman^{2,4}</p> <p>¹Neurocode - Bellingham, Washington (United States), ²BC Neuroimmunology - Vancouver (Canada), ³Cassava Sciences - Austin, Texas (United States), ⁴University of British Columbia - Vancouver (Canada), ⁵Northwest Pathology - Bellingham, Washington (United States)</p>

	<p>P112: Critical evaluation and comparison of biomarker values in commercial CSF with Lumipulse® to support assay development for clinical trials <u>Hugo Vanderstichele</u>¹, Mahsan Rafizadeh², Erika Cline², Johnson Derrick³, Erica Simmons³, Robert Dean², Jasna Jerecic² ¹Biomarkable - Gent (Belgium), ²Acumen Pharmaceuticals - Charlottesville (United States), ³B2S Life sciences - Indianapolis (United States)</p>
	<p>P113: Detection of CSF alpha-synuclein in patients with prodromal Lewy body disease <u>Melanie Plastini</u>¹, Carla Abdelnour¹, Marian Shahid¹, Manuel Medina², Nelson Kha², Hanna Hovren², Jennifer Lamoureux², Victor Henderson¹, Kathleen Poston¹ ¹Stanford University - Palo Alto (United States), ²Amprion Clinical Laboratory - San Diego (United States)</p>
	<p>P114: Effect of butyrylcholinesterase genotype on patients with Alzheimer's disease treated with rivastigmine <u>Hairin Kim</u>^{1,2}, So Yeon Cho³, Gieun Nam², Kichul Kim^{4,2}, Eosu Kim³, Jun-Young Lee² ¹Emocog Inc. - Seoul (Korea, Republic of), ²Department of Psychiatry, Seoul Metropolitan Government-Seoul National University Boramae Medical Center - Seoul (Korea, Republic of), ³Department of Psychiatry, Institute of Behavioral Science in Medicine, Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine - Seoul (Korea, Republic of), ⁴Epi Biotech Co., Ltd. - Incheon (Korea, Republic of)</p>
	<p>P115: Impact of Alzheimer's Disease Biomarker Disclosure to Cognitively Unimpaired Individuals: Experiences from a Truncated Randomized Phase 2b/3 Clinical Trial <u>Joshua Grill</u>¹, Rema Raman², Garrett Miller², Karin Ernstrom², Michael Donohue², Paul Aisen², Reisa Sperling³, David Henley⁴, H. Robert Brashear⁴, Gary Romano⁴, Gerald Novak⁴ ¹University of California Irvine - Irvine (United States), ²Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA - San Diego (United States), ³Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA - Boston (United States), ⁴Janssen Research & Development LLC - Titusville (United States)</p>
	<p>P116: Pharmacodynamic Effects of Semorinemab on Plasma and CSF Tau Biomarkers in a Phase 2 Trial in Mild-to-Moderate Alzheimer's Disease (Lauriet) <u>Stephen Schauer</u>¹, Julie Lee¹, Veronica Anania¹, Balazs Toth¹, Lee Honigberg¹, Kristin Wildsmith¹, Vidya Ramakrishnan¹, Michael Dolton¹, Sandra Sanabria Bohorquez¹, Edmond Teng¹, Cecilia Monteiro¹ ¹Genentech, Inc. - South San Francisco (United States)</p>
	<p>P117: Novel technology platform for the direct and sensitive detection of circulating AD-related molecules in blood. <u>Carine Lim</u>¹ ¹Sunbird Bio - Singapore (Singapore)</p>
	<p>P118: Recruitment of amyloid positive individuals and early Alzheimer's patients in a primary care setting – results from the BioFINDER Primary Care study <u>Sebastian Palmqvist</u>¹, Pontus Tideman¹, Erik Stomrud¹, Ruben Smith¹, Antoine Leuzy¹, Sadek Jafar Jasem¹, Niklas Mattsson-Carlgrén¹, Anna Orduña Dolado¹, Shorena Janelidze¹, Oskar Hansson¹ ¹Lund University - Malmö (Sweden)</p>
	<p>P119: Deep plasma and CSF proteomics profiling of the AMBAR study <u>Chunmiao (mia) Feng</u>¹, Ricardo Gonzalo², Carla Minguet², Pilar Lafuente², Ana Maria Ortiz², Scott Lohr¹, Mercè Boada³, Oscar López⁴, Antonio Paez², Steven Braithwaite¹, Montserrat Costa², Benoit Lehallier¹</p>

	¹ Alkahest, a Grifols company - San Carlos (United States), ² Grifols - Barcelona (Spain), ³ Universitat Internacional de Catalunya - Barcelona (Spain), ⁴ University of Pittsburgh - Pittsburgh (United States)
	P120: Association of neighborhood-level socioeconomic disadvantage with CSF biomarkers of Alzheimer's disease and neurodegeneration <u>Gilda Ennis</u> ¹ , Megan Zuelsdorff ¹ , Ryan Powell ¹ , Tobey Betthausen ¹ , William Buckingham ¹ , Yue Ma ¹ , Carol Van Hulle ¹ , Margherita Carboni ² , Gwendlyn Kollmorgen ³ , Carey Gleason ¹ , Sterling Johnson ¹ , Kaj Blennow ⁴ , Henrik Zetterberg ⁴ , Amy Kind ¹ , Barbara Bendlin ¹ ¹ University of Wisconsin - Madison - Madison (United States), ² Roche Diagnostics International Ltd - Rotkreuz (Switzerland), ³ Roche Diagnostics GmbH - Penzberg (Germany), ⁴ University of Gothenburg - Gothenburg (Sweden)
	P121: Plasma pTau-217 in preclinical Alzheimer's disease <u>Erin Jonaitis</u> ¹ , Shorena Janelidze ² , Karly Cody ¹ , Rebecca Langhough Kosciak ¹ , Lianlian Du ¹ , Nathaniel Chin ¹ , Niklas Mattsson-Carlsson ² , Kirk Hogan ¹ , Bradley Christian ¹ , Tobey Betthausen ¹ , Oskar Hansson ² , Sterling Johnson ¹ ¹ University of Wisconsin-Madison - Madison, WI (United States), ² Lund University - Lund (Sweden)
	P122: Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies <u>Stephanie Loomis</u> ¹ , Ryan Miller ¹ , Carmen Castrillo-Viguera ¹ , Kimberly Umans ¹ , Wenting Cheng ¹ , John O'gorman ¹ , Richard Hughes ¹ , Samantha Budd Haeberlein ¹ , Christopher Whelan ¹ ¹ Biogen - Cambridge (United States)
	P123: Low plasma Aβ42/Aβ40 ratio in older adults with enlarged perivascular spaces <u>Arunima Kapoor</u> ¹ , Aimee Gaubert ¹ , Amy Nguyen ¹ , Belinda Yew ² , Jung Yun Jang ¹ , Shubir Dutt ² , Yanrong Li ¹ , John P. Alitin ³ , Jean K Ho ¹ , Anna E. Blanken ² , Isabel J Sible ² , Anisa Marshall ² , Alessandra Martini ¹ , Elizabeth Head ¹ , Daniel A Nation ¹ ¹ University of California, Irvine - Irvine (United States), ² University of Southern California - Los Angeles (United States), ³ University of California, Irvine - Irvine (United States) - Irvine (United States)
	P124: NADALS: An open-label basket trial evaluating the JAK inhibitor baricitinib in Alzheimer's Disease and Amyotrophic Lateral Sclerosis <u>Shayda Daneshvari</u> ¹ , Pia Webb ¹ , Anne-Marie Wills ¹ , James Berry ¹ , Steven Arnold ¹ , Mark Albers ¹ ¹ MGH - Boston (United States)
	P125: Examining the trajectory of neurodegeneration biomarkers and its association with cognitive profiles and amyloid in late middle-aged adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP) <u>Lianlian Du</u> ^{1,2} , Tobey Betthausen ^{1,3,4} , Karly Cody ^{1,3,4} , Erin Jonaitis ^{1,3,4} , Cory Burghy ¹ , Bruce Hermann ^{1,5} , Bret Larget ⁶ , Rick Chappell ^{3,2} , Sterling Johnson ^{1,3,4,7} , Rebecca Kosciak ^{1,3,4} ¹ Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), ² Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison - Madison, WI (United States), ³ Wisconsin Alzheimer's Disease Research Center - Madison, WI (United States), ⁴ Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), ⁵ Department of Neurology, University of Wisconsin-Madison School of Medicine and Public Health - Madison, WI (United States), ⁶ Department of Statistics, University of Wisconsin-Madison - Madison, WI (United States), ⁷ Madison VA GRECC, William S. Middleton Memorial Hospital - Madison, WI (United States)

Theme: Cognitive and Functional Endpoints



	<p>P126: Visit-to-visit blood pressure variability and cognition in the SPRINT MIND trial <u>Isabel Sible</u>¹, Daniel Nation² ¹Usc - Los Angeles (United States), ²Uc Irvine - Irvine (United States)</p>
	<p>P127: Classification and Prediction of Different Cognitive Trajectories in Cognitively Normal Elderly Young Ju Kim¹, <u>Si Eun Kim</u>², Alice Hahn³, Soo Hyun Cho⁴, Duk L. Na¹, Jun Pyo Kim¹, Hyemin Jang¹, Hee Jin Kim¹, Juhee Chin¹, Sang Won Seo¹ ¹Samsung Medical Center - Seoul (Korea, Republic of), ²Haeundae Paik Hospital - Busan (Korea, Republic of), ³Johns Hopkins Bloomberg School Of Public Health - Baltimore (Korea, Republic of), ⁴Chonnam National University Hospital - Chonnam (Korea, Republic of)</p>
	<p>P128: What's in a score: Comparing and aligning scores based on item response theory and classical test theory for the Amsterdam Instrumental Activities of Daily Living Questionnaire <u>Mark Dubbelman</u>¹, Merel Postema¹, Roos Jutten², John Harrison¹, Craig Ritchie³, Benjamin Schalet⁴, Caroline Terwee⁵, Wiesje Van Der Flier¹, Philip Scheltens¹, Sietske Sikkes¹ ¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Umc Location Vumc - Amsterdam (Netherlands), ²Department Of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States), ³University Of Edinburgh - Edinburgh (United Kingdom), ⁴Department Of Medical Social Sciences, Feinberg School Of Medicine, Northwestern University - Chicago (United States), ⁵Amsterdam Umc Location Vumc, Epidemiology And Data Science, Amsterdam Umc - Amsterdam (Netherlands)</p>
	<p>P129: Effects of Dietary Flax Beverage on Memory and Cognition of Patients with Mild Cognitive Impairment <u>Aida Adlimoghaddam</u>¹, Nancy Olson², Benedict Albeni³ ¹Clinical Research Associate - Winnipeg (Canada), ²Clinical Trial Investigator (Canada), ³Professor (Canada)</p>
	<p>P130: A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Investigation of Safety and Efficacy of Nilotinib BE in Early Alzheimer's Disease (NILEAD) <u>Yasar Torres-Yaghi</u>¹, Marwan Sabbagh², Chris Hoyt³, Kimberly Guedes³, Fernando Pagan¹, Raymond Turner¹, Jaeil Ahn¹, Charbel Moussa¹ ¹Georgetown - Washington, DC (United States), ²Barrow - Phoenix, AZ (United States), ³Keiferx - Washington, DC (United States)</p>
	<p>P131: Subjective illness representations in an early-stage Alzheimer's disease population: psychometric properties of the RADIX questionnaire Alberto Villarejo-Galende¹, Elena García-Arcelay², Gerard Piñol-Ripoll³, Antonio Del Olmo-Rodríguez⁴, Felix Viñuela⁵, Mercè Boada⁶, Emilio Franco-Macías⁷, Almudena Ibañez De La Peña⁸, Mario Riverol⁹, <u>Jorge Maurino</u>² ¹Department Of Neurology, Hospital Universitario 12 De Octubre - Madrid (Spain), ²Medical Department, Roche Farma - Madrid (Spain), ³Unitat Trastorns Cognitius, Hospital Universitari De Santa Maria - Lleida (Spain), ⁴Department Of Neurology, Hospital Universitario Dr. Peset - Valencia (Spain), ⁵Department Of Neurology, Hospital Universitario Virgen Macarena - Sevilla (Spain), ⁶Ace Alzheimer Center Barcelona - Barcelona (Spain), ⁷Department Of Neurology, Hospital Universitario Virgen Del Rocío - Sevilla (Spain), ⁸Centro De Investigación De Parkinson, Policlínica Guipúzcoa - San Sebastián (Spain), ⁹Department Of Neurology, Clínica Universidad De Navarra - Pamplona (Spain)</p>

	<p>P132: Impact of Disease Progression on Dependency in Patients with Mild and Moderate Alzheimer Disease <u>Wenyu Ye</u>¹, Julie Chandler¹, Xiaojuan Mi², Antje Tockhorn-Heidenreich¹, Joseph Johnston¹, Erin Doty¹ ¹Eli Lilly And Company - Indianapolis (United States), ²Techdata Services Company - King Of Prussia (United States)</p>
	<p>P133: The responsiveness of cognitive and functional outcome measures in preclinical Alzheimer's disease: Implications for trial design <u>Mark Dubbelman</u>¹, Heleen Hendriksen¹, Lois Ottenhoff¹, Everard Vijverberg¹, Niels Prins², Lior Kroeze¹, Argonde Van Harten¹, Bart Van Berckel¹, John Harrison¹, Wiesje Van Der Flier¹, Sietske Sikkes¹ ¹Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Umc Location Vumc - Amsterdam (Netherlands), ²Brain Research Center - Amsterdam (Netherlands)</p>
	<p>P134: The effect of dietary habit on the progression of Alzheimer's disease: A CREDOS (Clinical Research Center for Dementia of South Korea) study <u>Yangki Minn</u>¹, Seonghye Choi² ¹Kangnam Sacred Heart Hospital, Hallym University - Seoul (Korea, Republic of), ²Inha University Medicval Center - Incheon (Korea, Republic of)</p>
	<p>P135: Length of administration of ADAS-Cog and CDR assessment impacts data quality <u>Barbara Echevarria</u>¹ ¹WCG Clinical Endpoint Solutions - Hamilton (United States)</p>
	<p>P136: Measuring functional impairment in early Alzheimer's disease and related disorders: an overview of the development and validation of the Amsterdam IADL Questionnaire <u>Sietske Sikkes</u>¹, Mark Dubbelman², Merel Postema², Merike Verrijp³, Freek Gilissen², Wiesje Van Der Flier², Yolande Pijnenburg², Philip Scheltens² ¹Vu University / Amsterdam Umc - Amsterdam (Netherlands), ²Amsterdam Umc, Alzheimer Center - Amsterdam (Netherlands), ³Brain Research Center - Amsterdam (Netherlands)</p>
	<p>P137: A Phase 2b, Randomized, Placebo-Controlled Trial to Evaluate the Effects of SAGE-718 in Patients with Alzheimer's Disease: Study Design Aaron Koenig¹, <u>Tiffany Lago</u>¹, Jason Johannesen¹, Sigui Li¹, Emily Freitag¹, Jeffrey Wald¹, Katrina Paumier¹, Michael Quirk¹, James Doherty¹ ¹Sage Therapeutics, Inc. - Cambridge, Massachusetts (United States)</p>
	<p>P138: Bringing meaning to personalised Brain Health: a tool that empowers individuals to define and monitor personally meaningful change <u>Stina Saunders</u>¹, David Bates², Ankur Bharija^{2,3}, Joyce Gomes-Osman^{2,4}, Saturnino Luz¹, Graciela Muniz-Terrera¹, Álvaro Pascual-Leone^{2,5}, Craig Ritchie¹ ¹Centre for Clinical Brain Sciences, University of Edinburgh, UK - Edinburgh (United Kingdom), ²Linus Health Inc., Boston, MA, USA - Boston (United States), ³Department of Medicine, Division of Primary Care and Population Health, Stanford Medicine, Stanford, USA - Stanford (United States), ⁴Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA - Miami (United States), ⁵Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA - Boston (United States)</p>
	<p>P139: Dementia conversion rate differences between patients with high- and low-risk amnesic mild cognitive impairment in the real-world: A prospective, multicenter, observational study <u>Hyemin Jang</u>¹, Duk L. Na², Jay Cheol Kwon³, Mee Young Park⁴, Yeonsil Moon⁵, Jung Seok Lee⁶, Kyung-Won Park⁷, Ae Young Lee⁸, Hanna Cho⁹, Jae-Hong Lee¹⁰, Byeong Chae Kim¹¹, Kee Hyung</p>







	<p>Park ¹², Byung-Chul Lee ¹³, Hojin Choi ¹⁴, Kim Jieun ¹⁵, Na-Yeon Jung ¹⁶ ¹Samsung Alzheimer's Convergence Research Center, Samsung Medical Center - Seoul (Korea, Republic of), ²Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul (Korea, Republic of), ³Department of Neurology, Changwon Fatima Hospital - Changwon (Korea, Republic of), ⁴Department of Neurology, Yeungnam University College of Medicine - Daegu (Korea, Republic of), ⁵Department of Neurology, Konkuk University Medical Center, Konkuk University School of Medicine - Seoul (Korea, Republic of), ⁶Department of Neurology, Jeju National University College of Medicine - Jeju (Korea, Republic of), ⁷Department of Neuroscience, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health - Busan (Korea, Republic of), ⁸Department of Neurology, Chungnam National University School of Medicine - Daejeon (Korea, Republic of), ⁹Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), ¹⁰Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine - Seoul (Korea, Republic of), ¹¹Department of Neurology, Chonnam National University Medical School & Hospital - Gwangju (Korea, Republic of), ¹²Department of Neurology, College of Medicine, Gachon University Gil Hospital - Incheon (Korea, Republic of), ¹³Department of Neurology, Hallym University College of Medicine - Seoul (Korea, Republic of), ¹⁴Department of Neurology, Hanyang University Guri Hospital - Guri (Korea, Republic of), ¹⁵Department of Medical, Eisai Korea Inc. - Seoul (Korea, Republic of), ¹⁶Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine - Yangsan (Korea, Republic of)</p>
	<p>P140: Predicting tau PET signal in prodromal-to mild Alzheimer's disease from speech biomarkers and machine learning Mario Mina ¹, Johannes Troeger ¹, Louisa Schwed ¹, <u>Nicklas Linz</u> ¹, Sandra Sanabria Bohórquez ², Somaye Hashemifar ², Tina Boggiano ³, Edmond Teng ² ¹ki:elements - Saarbruecken (Germany), ²Genentech Inc - San Francisco (United States), ³F. Hoffmann-La Roche Ltd - Basel (Switzerland)</p>







Posters presented on Friday, December 2nd from 8am to 5pm

Theme: Cognitive assessment and clinical trials



	<p>P141: SKT Short Cognitive Performance Test for the detection of early cognitive decline – data from international validation studies <u>Mark Stemmler</u> ¹ ¹University Of Erlangen-Nuremberg - Erlangen (Germany)</p>
	<p>P142: ImPACT Cognitive Assessment: What are we measuring <u>James Gyurke</u> ¹, Phiil Schatz ² ¹Riverside Insights - Lutz (United States), ²Saint Joseph's University - Philadelphia (United States)</p>
	<p>P143: The effects of the home-based tDCS on behavioral and electrophysiological parameters in MCI and AD comorbid with depression: <u>Do Hoon Kim</u> ¹, Yoo Sun Moon ¹ ¹Chunbceon Sacred Heart Hospital - Chuncheon (Korea, Republic of)</p>
	<p>P144: Early-life factors and risk of incident dementia: a longitudinal cohort study <u>Ya-Nan Ou</u> ¹ ¹Qingdao Municipal Hospital - Qingdao (China)</p>

	<p>P145: Association of socioeconomic status and lifestyle with incident dementia: a prospective cohort study of 276730 UK Biobank participants</p> <p><u>Ya-Nan Ou</u>¹</p> <p>¹<i>Qingdao Municipal Hospital - Qingdao (China)</i></p>
	<p>P146: Association of long-term exposure to ambient air pollution with cognitive decline and Alzheimer's disease-related amyloidosis</p> <p><u>Ya-Hui Ma</u>¹, Lan Tan², Jin-Tai Yu³</p> <p>¹<i>Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Qingdao (China) - Qingdao (China)</i>, ²<i>Qingdao Municipal Hospital, College Of Clinical Medicine, Qingdao University - Qingdao (China)</i>, ³<i>Department Of Neurology And Institute Of Neurology, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University - Shanghai (China)</i></p>
☒	<p>P147: Pre-Screening Prodromal AD Trial Populations over the Telephone Using a Speech Biomarker for Cognition — Preliminary Results from AUTONOMY Phase 2 AD Trial Recruitment</p> <p><u>Stephen Ruhmel</u>¹, Johannes Tröger², Nicklas Linz², Janna Herrmann², Kai Langel³</p> <p>¹<i>The Janssen Pharmaceutical Companies Of Johnson & Johnson (United States)</i>, ²<i>Ki:elements - Saarbrücken (Germany)</i>, ³<i>Ki:elements (United States)</i></p>
☒	<p>P148: The difference in trajectories according to early amyloid accumulation in normal cognitive elderly</p> <p><u>Young Ju Kim</u>¹, Min Young Chun¹, Hyemin Jang¹, Hee Jin Kim¹, Jeong-Yeon Seo¹, Sang Won Seo¹</p> <p>¹<i>Samsung Medical Center - Seoul (Korea, Republic of)</i></p>
	<p>P149: Risk of seizures and subclinical epileptiform activity in patients with dementia: a systematic review and meta-analysis</p> <p><u>Bing Zhao</u>¹</p> <p>¹<i>Qingdao Municipal Hospital - Qingdao (China)</i></p>
☒	<p>P150: Preliminary psychometric and clinical validation of information processing speed in early Alzheimer's Disease using a smartphone-based remote assessment</p> <p><u>Arnaud M. Wolfer</u>¹, Irma T. Kurniawan¹, Kirsten I. Taylor¹, Florian Lipsmeier¹, Thanneer M. Perumal¹</p> <p>¹<i>Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 - Basel (Switzerland)</i></p>
	<p>P151: Differential associations of ApoE-ε2 and ApoE-ε4 genotypes with cerebrospinal fluid biomarkers of Alzheimer's disease in individuals without dementia</p> <p><u>Bing Zhao</u>¹</p> <p>¹<i>Qingdao Municipal Hospital - Qingdao (China)</i></p>
☒	<p>P152: Preliminary psychometric and clinical validation of executive function in early Alzheimer's diseases using a smartphone-based assessment</p> <p><u>Irma T. Kurniawan</u>¹, Arnaud M. Wolfer¹, Christopher Chatham¹, Eduardo Aponte¹, Stefan Holiga¹, Thanneer M. Perumal¹, Kirsten I. Taylor¹</p> <p>¹<i>Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124 - Basel (Switzerland)</i></p>
☒	<p>P153: Preliminary psychometric and clinical validation of visuospatial working memory deficits in early Alzheimer's Disease measured with a smartphone based digital assessment</p> <p><u>Eduardo A. Aponte</u>¹, Kirsten I. Taylor¹, Arnaud M. Wolfer¹, Christopher Chatham¹, Thanneer M. Perumal¹</p> <p>¹<i>Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124 - Basel (Switzerland)</i></p>




	<p>P154: The Phase 2 LUMINARY Trial Assessing SAGE-718 in Patients with Mild Cognitive Impairment or Mild Dementia due to Alzheimer's Disease Aaron Koenig ¹, Shishuka Malhotra ², Jeffrey Wald ¹, Jennifer Petrillo ¹, <u>Katrina Paumier</u> ¹, Jason Johannesen ¹, Sigui Li ¹, Michael Quirk ¹, Emily Freitag ¹, James Doherty ¹ ¹<i>Sage Therapeutics, Inc. - Cambridge, Massachusetts (United States)</i>, ²<i>Neuro-Behavioral Clinical Research, Inc. - North Canton, Ohio (United States)</i></p>
	<p>P155: Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Dementia <u>Kayden Mimmack</u> ¹, Emily Sprague ^{2,3}, Rebecca Amariglio ^{1,2,3}, Patrizia Vannini ^{1,2,3}, Gad Marshall ^{1,2,3} ¹<i>Department of Neurology, Massachusetts General Hospital, Harvard Medical School - Boston (United States)</i>, ²<i>Department of Neurology, Brigham and Women's Hospital, Harvard Medical School - Boston (United States)</i>, ³<i>Center for Alzheimer Research and Treatment - Boston (United States)</i></p>
	<p>P156: Potential Influence of Cognitive Heterogeneity in a Clinical Trial for Mild-to-Moderate Probable Alzheimer's Dementia <u>Diane Jacobs</u> ¹, Yuqi Qiu ², David Salmon ¹, Karen Messer ¹, Lia Donahue ³, Steven Kaplita ³, Irfan Qureshi ³, Howard Feldman ¹ ¹<i>University of California San Diego - La Jolla (United States)</i>, ²<i>School of Statistics, East China Normal University - Shanghai (China)</i>, ³<i>Biohaven Pharmaceuticals, Inc - New Haven (United States)</i></p>
	<p>P157: Impact of Different Rates of Disease Progression in Individuals with Amyloid Positive Alzheimer's Disease - Findings from the Alzheimer's Disease Neuroimaging Initiative <u>Julie M Chandler</u> ¹, Mihaela Georgieva ², Urvi Desai ², Noam Kirson ², Wenyu Ye ¹, Andres Gomez-Lievano ², Annalise Hilts ³, Dody Eid ², Angela Zhao ², Traci Schilling ¹ ¹<i>Eli Lilly and Company - Indianapolis (United States)</i>, ²<i>Analysis Group - Boston (United States)</i>, ³<i>Groupe d'Analyse - Montréal (Canada)</i></p>
	<p>P158: Association of peripheral immunity with cognition, neuroimaging, and Alzheimer's pathology <u>Jia Hui Hou</u> ¹, Jin Tai Yu ² ¹<i>Department of Neurology, Qingdao Municipal Hospital, Q - Qing Dao (China)</i>, ²<i>Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, - Shang Hai (China)</i></p>
	<p>P159: Clinical predictors for conversion to Alzheimer's dementia in patients with mild cognitive impairment using Amyloid PET imaging : Interim results <u>Kyung Won Park</u> ¹, Seon-Jeong Kim ¹, Do-Young Kang ², Young-Jin Jeong ² ¹<i>Department of Neurology, Dong-A University College of Medicine - Busan (Korea, Republic of)</i>, ²<i>Department of Nuclear Medicine, Dong-A University College of Medicine - Busan (Korea, Republic of)</i></p>
	<p>P160: Implementation of the Integrated Cognitive Assessment for Screening and Triaging of Individuals at Risk of Dementia <u>Seyed-Mahdi Khaligh-Razavi</u> ¹, Chris Kalafatis ^{1,2}, Nahida Ahmed ³, Tareq Qassem ⁴, Farooq Khan ⁵ ¹<i>Cognetivity Neurosciences - London (United Kingdom)</i>, ²<i>Kings College London University - London (United Kingdom)</i>, ³<i>Chair of Behavioral Health Council-SEHA - Abu Dhabi (United Arab Emirates)</i>, ⁴<i>Maudsley Health, Al-Amal Psychiatric Hospital - Dubai (United Arab Emirates)</i>, ⁵<i>Birmingham & Solihull Mental Health NHS Foundation Trust - London (United Kingdom)</i></p>
	<p>P161: Impact of Different Rates of Disease Progression in Individuals with Amyloid Positive Alzheimer's Disease - Findings from the National Alzheimer's Coordinating Center <u>Julie M Chandler</u> ¹, Mihaela Georgieva ², Urvi Desai ², Noam Kirson ², Wenyu Ye ¹, Angela Zhao ², Dody Eid ², Andres Gomez-Lievano ², Annalise Hilts ³, Traci Schilling ¹ ¹<i>Eli Lilly and Company - Indianapolis (United States)</i>, ²<i>Analysis Group - Boston (United States)</i>, ³<i>Groupe d'Analyse - Montréal (Canada)</i></p>

	<p>P162: Evaluation of cognitive decline in seniors using a single-channel EEG with auditory cognitive assessment</p> <p><u>Lior Molcho</u>¹, Neta Batya Maimon^{2,1}, Talya Zeimer¹, Noa Regev-Plotnik³, Sarit Rabinowicz³, Nathan Intrator^{1,4,5}, Ady Sasson³</p> <p>¹Neurosteer Inc. - New York, Ny (United States), ²The School of Psychological Sciences, Tel Aviv University - Tel Aviv-Yafo (Israel), ³Dorot Geriatric Medical Center - Netanya (Israel), ⁴Blavatnik School of Computer Science, Tel Aviv University - Tel Aviv (Israel), ⁵Sagol School of Neuroscience, Tel Aviv University, - Tel Aviv (Israel)</p>
	<p>P163: Predictors of memory impairment in mild cognitive impairment with low Mini-Mental State Examination recall scores</p> <p><u>Seon Young Ryu</u>¹, Sang Bong Lee¹, Taek Jun Lee¹, Yu Jin Jung¹</p> <p>¹The Catholic University of Korea, Daejeon St. Mary's Hospital - Daejeon (Korea, Republic of)</p>
	<p>P164: Increased numbers of modifiable dementia risk factors amplify adverse effects on cognition across the adult lifespan.</p> <p>Annalise Laplume¹, <u>Larissa Mcketton</u>¹, Brian Levine^{1,2,3}, Angela Troyer^{4,5}, Nicole Anderson^{1,2,6}</p> <p>¹Rotman Research Institute, Baycrest Health Sciences - Toronto (Canada), ²Department of Psychology, University of Toronto - Toronto (Canada), ³Department of Medicine (Neurology), University of Toronto - Toronto (Canada), ⁴Department Of Psychology, University Of Toronto - Toronto (Canada), ⁵Neuropsychology and Cognitive Health Program, Baycrest Health Sciences - Toronto (Canada), ⁶Department of Psychiatry, University of Toronto - Toronto (Canada)</p>
	<p>P165: Feasibility, Reliability, and Validity of Remote Smartphone Data Collection in Frontotemporal Dementia using the ALLFTD Mobile App</p> <p><u>Adam Staffaroni</u>¹, Jack Taylor¹, Annie Clark¹, Hilary Heuer¹, Amy Wise¹, Masood Manoochehri², Leah Forsberg³, Carly Mester³, Meghana Rao³, Danielle Brushaber³, Julio Rojas¹, Joel Kramer¹, Bradley Boeve³, Howard Rosen¹, Adam Boxer¹</p> <p>¹UCSF - San Francisco (United States), ²Columbia University - New York (United States), ³Mayo Clinic - Rochester (United States)</p>
	<p>P166: Calculating Generalized Recall Probability Using Digital Cognitive Biomarkers Derived from Wordlist Memory Test Assessment</p> <p><u>Junko Hara</u>^{1,2}, Jason Bock^{1,3}, Kaavya Shah⁴, Dennis Fortier¹, Michael Lee³</p> <p>¹Embic Corporation - Newport Beach (United States), ²Pickup Family Neuroscience Institute and Hoag Center for Research and Education, Hoag Memorial Hospital - Newport Beach (United States), ³Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), ⁴University of California at Berkeley - Berkeley (United States)</p>
	<p>P167: Digital Cognitive Biomarkers for the ADAS-Cog Word Recall Test: Accuracy and Validity of Classifying Cognitive Impairment</p> <p><u>Jason Bock</u>^{1,2}, Junko Hara^{1,3}, Dennis Fortier¹, Tushar Mangrola¹, William Shankle^{1,2,3}, Michael Lee²</p> <p>¹Embic Corporation - Newport Beach (United States), ²Dept. of Cognitive Sciences, University of California at Irvine - Irvine (United States), ³Pickup Family Neuroscience Institute, Hoag Memorial Hospital - Newport Beach (United States)</p>
	<p>P168: A novel 2-minute high-frequency assessment of episodic memory, shows diurnality, time varying patterns in fatigue and mood which become more tightly coupled with age.</p> <p><u>Alexander Anwyl-Irvine</u>¹, Alexander Kaula¹, Nick Taptiklis¹, Cashdollar Nathan¹, Francesca Cormack¹</p> <p>¹Cambridge Cognition - Cambridge (United Kingdom)</p>





Theme: Behavioral disorders and clinical trials

	<p>P169: A proof-of-concept study to evaluate efficacy of NanoLithium on the progression of Neuropsychiatric symptoms in patients with mild-to-severe Alzheimer's disease. <u>Maria Soto</u>¹, Solene Guilliot², Pierre-Jean Ousset¹, Davide Angioni¹, Nathalie Sastre Hengan¹, Jean-Claude Maurel², Jacques Touchon³ ¹Department Of Geriatrics, Gerontopole, University Hôpital Toulouse, France - Toulouse (France), ²Medesis Pharma - Baillargues (France), ³Montpellier School Of Medecine; University Of Montpellier - Montpellier (France)</p>
	<p>P170: Mild behavioral impairment correlates of cognitive impairments in older adults without dementia: Mediation by amyloid pathology Jin-Tai Yu¹, <u>Lan Tan</u>² ¹Department Of Neurology And Institute Of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China-Shanghai (china) - Shanghai (China) - Shanghai (China), ²Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China - Qingdao (China)</p>
	<p>P171: sTREM2 mediates the associations of minimal depressive symptoms with amyloid pathology in prodromal Alzheimer's disease: The CABLE study <u>Wang Zhibo</u>¹ ¹Qingdao University - Qingdao (China)</p>

Theme: Health economics and clinical trials



	<p>P172: Health economic considerations in the development of a preventive Alzheimer's treatment <u>Soeren Mattke</u>¹, Kate Jun¹, Samantha Chu², Mark Hanson¹, Eric Reiman³, Jeffrey Kordower⁴ ¹University Of Southern California - Los Angeles (United States), ²Cornell University - Ithaca (United States), ³Banner Alzheimer's Institute - Phoenix (United States), ⁴Arizona State University - Tempe (United States)</p>
	<p>P173: Long-Term Care Insurance Service Utilization pattern according to clinical factors of Dementia <u>Jun Hong Lee</u>¹ ¹National Health Insurance Service Ilsan Hospital - Goyang-Si (Korea, Republic of)</p>
	<p>P174: Cataract, cataract surgery, and risk of incident dementia: a prospective cohort study of 300,823 participants <u>Lingzhi Ma</u>¹, Lan Tan¹, Jintai Yu² ¹Department Of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. - Qingdao (China), ²Department Of Neurology And National Center For Neurological Disorders, Huashan Hospital, State Key Laboratory Of Medical Neurobiology And Moe Frontiers Center For Brain Science, Shanghai Medical College, Fudan University, Shanghai, China. - Shanghai (China)</p>
	<p>P175: Bridging clinical trials and health economic models in Alzheimer's disease <u>Linus Jonsson</u>¹, Ron Handels², Colin Green¹ ¹Karolinska Institutet - Stockholm (Sweden), ²Maastricht University - Maastricht (Netherlands)</p>



Theme: Epidemiology and clinical trials

	<p>P176: Identification of medical conditions as risk factors for mild cognitive impairment – a US claims database study <u>Gang Li</u>¹, Toschi Nicola², Batrla Richard³, Galvin James⁴, Henley David⁵, De Santi Susan⁶, Hampel Harald⁶ ¹Eisai Inc - Hillsborough (United States), ²Rome University - Rome (Italy), ³Eisai Inc - Basel (Swaziland), ⁴Miami University - Miami (United States), ⁵Janssen - Indianapolis (United States), ⁶Eisai Inc - Nutley (United States)</p>
	<p>P177: Safety of fluorine 18-labeled amyloid tracers: pharmacovigilance validation using a large real-world database <u>Kenichiro Sato</u>¹, Yoshiaki Niimi², Ryoko Ihara³, Kazushi Suzuki⁴, Atsushi Iwata³, Takeshi Iwatsubo¹ ¹University Of Tokyo - Tokyo (Japan), ²University Of Tokyo Hospital - Tokyo (Japan), ³Tokyo Metropolitan Geriatric Medical Center Hospital - Tokyo (Japan), ⁴National Defense Medical College - Saitama (Japan)</p>
	<p>P178: Diagnosis and clinical trial recruitment of patients with early onset Alzheimer’s disease in clinical practice: Single center experience in Japan <u>Masanori Kurihara</u>¹, Ryoko Ihara¹, Kenji Ishibashi², Kenji Ishii², Kazutomi Kanemaru¹, Atsushi Iwata¹ ¹Department Of Neurology, Tokyo Metropolitan Geriatric Hospital And Institute Of Gerontology - Tokyo (Japan), ²Research Team For Neuroimaging, Tokyo Metropolitan Geriatric Hospital And Institute Of Gerontology - Tokyo (Japan)</p>
	<p>P179: Socioeconomic status and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 39 prospective studies <u>Anyi Wang</u>¹ ¹Qingdao University, Qingdao, China - Qingdao (China)</p>
	<p>P180: Globalization of Alzheimer disease clinical trials: recommendations for trial implementation in low- and middle-income countries. <u>Jorge Llibre-Guerra</u>¹ ¹Washington University School Of Medicine In St.louis - St. Louis (United States)</p>
	<p>P181: Association between multimorbidity status and incident dementia: A prospective cohort study of 245,483 participants <u>Heying Hu</u>¹, Jintai Yu², Lan Tan¹ ¹Qingdao University - Qingdao (China), ²Fudan University - Shanghai (China)</p>
	<p>P182: Generalizability of cognitive results from clinical trial participants to older adult population: addressing external validity <u>Vahan Aslanyan</u>¹, Howard N. Hodis^{1,2,3}, Jan St. John^{1,2}, Naoko Kono^{1,2}, Victor Henderson⁴, Wendy J Mack¹ ¹Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), ²Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), ³Department of</p>

	<p>Medicine, Keck School of Medicine, University of Southern California - Los Angeles, Ca (United States), ⁴Department of Epidemiology and Department of Neurology and Neurological Sciences, School of Medicine, Stanford University - Stanford, Ca (United States)</p>
	<p>P183: Cholinesterase inhibitors are associated with large reduction in mortality in patients with Alzheimer's dementia and heart failure <u>Maria Eriksdotter</u>¹, Marianne Reimers Wessberg², Johan Fastbom³, Ake Seiger², Hong Xu⁴ ¹Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical geriatrics and Theme Inflammation and Aging, Karolinska University Hospital, Huddinge - Stockholm (Sweden), ²Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical geriatrics - Stockholm (Sweden), ³Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Aging Research Center - Stockholm (Sweden), ⁴Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Clinical geriatrics - Stockholm (Sweden) - Stockholm (Sweden)</p>
	<p>P184: Association between Life's Simple 7 with cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study <u>Yong-Li Zhao</u>¹, Jin-Tai Yu² ¹Department of Neurology, Qingdao Municipal Hospital, Qingdao University - Qingdao (China), ²Department of Neurology and Institute of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontier Center for Brain Science, Shanghai Medical College, Fudan University - Shanghai (China)</p>
	<p>P185: Hypnotics predict incident dementia and Alzheimer's disease: ADNI cohort and updated meta-analysis of published longitudinal studies <u>Jia Hui Hou</u>¹, Wei Xu¹ ¹Department of Neurology, Qingdao Municipal Hospital, Qingdao University - Qing Dao (China)</p>
	<p>P186: Ultra high risk and high predictability of Alzheimer's disease onset in people with Down syndrome: implications for clinical trials <u>Juan Fortea</u>^{1,2,3}, Alberto Lleo^{1,2}, Alexandre Bejanin^{1,2}, Maria Florencia Iulita^{1,2} ¹Memory Unit and Biomedical Research Institute Sant Pau (IIB Sant Pau), Neurology Department, Hospital de la Santa Creu i Sant Pau - Barcelona (Spain), ²Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED) - Madrid (Spain), ³Barcelona Down Medical Center, Fundació Catalana Síndrome de Down - Barcelona (Spain)</p>






Theme: Animal Models and Clinical Trials



	<p>P187: Antidiabetic Drugs in the treatment of Alzheimer's Disease: Perspective from a Drosophila model of Tauopathy and neuroblastoma cells <u>Shreyasi Chatterjee</u>¹ ¹Nottingham Trent University - Nottingham (United Kingdom)</p>
	<p>P188: A novel small molecule inhibitor reduces toxic amyloid oligomers to rescue disease in AD mice <u>Vidhu Mathur</u>¹, Kevin Burk¹, Xikun Liu², Sagar Gaikwad³, Rakez Kaye³, Michael T Bowers², Katie Planey¹, Ambuj Singh⁴ ¹Acelot Inc. - Santa Barbara (United States), ²Department of Chemistry and Biochemistry, University</p>

	<i>of California - Lubbock (United States), ³Departments of Neurology & Neuroscience & Cell Biology & Anatomy, University of Texas Medical Branch - Galveston (United States), ⁴Acelot Inc - Santa Barbara (United States)</i> 00295
	P189: T-type calcium channel modulator AD101 improves cognitive function in animal models of memory and learning impairment and provides a rationale for the potential clinical use of AD101 in the symptomatic treatment of Alzheimer's disease <u>Jan Burmeister</u> ¹ , Serge Gauthier ² , Sharon Rogers ¹ ¹ AmyriAD Pharma, Inc. - Los Angeles (United States), ² McGill University - Montréal (Canada)
	P190: Effects of T-type calcium channel modulator AD101 on the accumulation of Beta Amyloid, Tau and polyubiquitinated proteins in animal models of Alzheimer's Disease <u>Jan Burmeister</u> ¹ , Serge Gauthier ² , Sharon Rogers ¹ ¹ AmyriAD Pharma, Inc. - Los Angeles (United States), ² McGill University - Montréal (Canada)


Theme: Proof of Concept/Translational research for Alzheimer Drug Development interventions




	P191: Investigating the Efficacy of Tolfenamic acid and its Analogs as Potential Alzheimer's disease Therapeutics Jaunetta Hill ¹ , <u>Nasser Zawia</u> ^{2,3,4,5} ¹ Department Of Biomedical And Pharmaceutical Sciences, University Of Rhode Island - Kingston (United States), ² Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation - Doha (Qatar), ³ Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island - Kingston (United States), ⁴ Interdisciplinary Neuroscience Program and George and Anne Ryan Institute for Neuroscience, University of Rhode Island - Kingston (United States), ⁵ George and Anne Ryan Institute for Neuroscience, University of Rhode Island - Kingston (United States)
	P192: XanaMIA Phase 1b trial with Xanamem® achieves primary endpoints: results and strategic update <u>Michael Woodward</u> ¹ , Paul Rolan ² , Miriam Roesner ² , Jack Taylor ² , Tamara Miller ² , Paul Maruff ³ ¹ Aged Care Research And Memory Clinic, Austin Health - Melbourne (Australia), ² Actinogen Medical - Sydney (Australia), ³ Cogstate Ltd - Melbourne (Australia)
	P193: Leveraging untapped national synergies to accelerate representation of Hispanic/Latinos in clinical trials on dementia: the progress of the new Consorcio between the National Association of Hispanic Nurses and the Alzheimer's Association <u>Elena Portacolone</u> ¹ , Adriana Perez ² , Carl V. Hill ³ , Julio C. Rojas ¹ ¹ University California San Francisco - San Francisco (United States), ² Penn University - Philadelphia (United States), ³ Alzheimer's Association - Chicago (United States)
	P194: Chronic constant light disrupted Circadian Rhythm and induced Alzheimer's Disease-Like Pathology in Rodent and treatment by Fluoxetine Ashish Sharma ¹ , Mohammad Ashu ² , Adesh K Saini ³ , <u>Rohit Goyal</u> ² ¹ Washington University - Missouri (United States), ² Shoolini University - Solan (India), ³ Mm University - Ambala (India)
	P195: Astrocytic Regulatory mechanism on PM2.5-induced neuronal cell death and neuroinflammation <u>Seol-Heui Han</u> ¹ , Ryeong-Eun Kim ² , Kyoung Ja Kwon ^{2,3} ¹ Department Of Neurology, Konkuk Hospital Medical Center, 120-1 Neungdong-Ro, Gwangjin-Gu -






	<p>Seoul (Korea, Republic of), ²Department Of Neuroscience, School Of Medicine, Konkuk University - Seoul (Korea, Republic of), ³Department of Neurology, Konkuk Hospital Medical center, 120-1 Neungdong-ro, Gwangjin-Gu - Seoul (Korea, Republic of)</p>
	<p>P196: Impact of Semaglutide in Amyloid Positivity (ISAP): Protocol for a Randomised Double-Blind Placebo-Controlled Trial in Amyloid Positive Individuals <u>Ivan Koychev</u>¹, Amanda Adler¹, Paul Edison², Brian Tom³, Joanne Milton¹, Joe Butchart⁴, Adam Hampshire², Charles Marshall⁵, Elizabeth Coulthard⁶, Henrik Zetterberg⁷, Francesca Cormack⁸, Catherine Mummery⁹, Rury Holman¹ ¹University of Oxford - Oxford (United Kingdom), ²Imperial College London - London (United Kingdom), ³University of Cambridge - Cambridge (United Kingdom), ⁴Royal Devon University Healthcare NHS Foundation Trust - Exeter (United Kingdom), ⁵Queen Mary University of London - London (United Kingdom), ⁶University of Bristol - Bristol (United Kingdom), ⁷University of Gothenburg - Gothenburg (United Kingdom), ⁸Cambridge Cognition - Cambridge (United Kingdom), ⁹University College London - London (United Kingdom)</p>
	<p>P197: The novel FKBP51-Hsp90 interaction inhibitor attenuates high-fat-induced cognitive impairment <u>Bengt Winblad</u>¹, Lisha Wang¹, Jakub Wojcieszak¹, Rajnish Kumar¹, Pavel Pavlov¹ ¹Karolinska Institutet - Stockholm (Sweden)</p>
	<p>P198: Intracellular Aβ accumulation in hippocampal neurons leads to endosomal/lysosomal leakage <u>Sophia Schedin Weiss</u>¹, Yang Gao¹, Lars Tjernberg¹ ¹Karolinska Institutet - Solna (Sweden)</p>
	<p>P199: ALZ-201, a monoclonal antibody therapy for specific neutralisation of toxic amyloid-β in Alzheimer's disease <u>Anders Sandberg</u>¹ ¹Alzinova AB - Gothenburg (Sweden)</p>
	<p>P200: Reducing toxic amyloid-β oligomers in AD through precise targeting of the molecular mechanisms of oligomer formation with small molecule inhibitors <u>Johnny Habchi</u>¹, Kerry Jenkins¹, Samata Pandey¹, Roxine Staats¹, Sunehera Sarwat¹, Benedetta Mannini¹, Xiaoting Yang¹, Luke Rajah¹, Samuel Cohen¹, Suzanne Brewerton¹, Alleyn Plowright¹ ¹Wren Therapeutics Limited - Cambridge (United Kingdom)</p>
	<p>P201: The bromodomain and extraterminal domain protein inhibitor apabetalone inhibits the neurotoxic kynurenine pathway in monocytes and brain endothelial cells Sylwia Wasiak¹, Li Fu¹, Stephanie Stotz¹, Dean Gilham¹, Laura Tsujikawa¹, Chris Sarsons¹, Jeffrey Kroon², Erik Stroes², Norman Wong¹, Michael Sweeney³, <u>Jan Johansson</u>³, Ewelina Kulikowski¹ ¹Resverlogix - Calgary (Canada), ²University of Amsterdam - Amsterdam (Netherlands), ³Resverlogix - San Francisco (United States)</p>
	<p>P202: A novel therapeutic approach to treat Alzheimer's disease: The brain-specific signal peptide peptidase-like 2b (SPPL2b) <u>Simomne Tambaro</u>¹, Riccardo Maccioni², Caterina Travan³, Stefania Zerial³, Annika Wagener⁴, Yuniesky Andrade-Talavera¹, Federico Picciau², Caterina Grassi⁵, Gefei Chen⁶, André Fisahn¹, Bernd Schröder⁷, Per Nilsson¹ ¹Department of Neurobiology, Care Sciences and Society (NVS) Division of Neurogeriatrics, Karolinska Institutet - Solna (Sweden), ²Department of Biomedical Sciences, Neuroscience and Clinical Pharmacology, University of Cagliari - Cagliari (Italy), ³Department of life science, University of Trieste - Trieste (Italy), ⁴Interdisciplinary center for Neuroscience, Heidelberg University -</p>

	<p>Heidelberg (Germany), ⁵Department of Pharmacy and Biotechnology, University of Bologna - Bologna (Italy), ⁶Department of Biosciences and Nutrition, Karolinska Institutet - Huddinge (Sweden), ⁷Institute of Physiological Chemistry, Technische Universität Dresden - Dresden (Germany)</p>
	<p>P203: Increased CSF-decorin predicts brain pathological changes driven by Alzheimer's Aβ amyloidosis Richeng Jiang ¹, Una Smailovic ¹, Hazal Haytural ¹, Betty Tijms ², Hao Li ¹, Ganna Shevchenko ³, Johan Gobom ⁴, Sofie Nyström ⁵, Per Hammarström ⁵, Stina Syvänen ³, Henrik Zetterberg ⁴, Bengt Winblad ¹, Jonas Bergquist ³, Pieter Jelle Visser ², <u>Per Nilsson</u> ¹ ¹Karolinska Institutet - Stockholm (Sweden), ²Amsterdam UMC - Amsterdam (Netherlands), ³Uppsala University - Uppsala (Sweden), ⁴Sahlgrenska Academy at the University of Gothenburg - Gothenburg (Sweden), ⁵Linköping University - Linköping (Sweden)</p>
	<p>P204: Antibodies generated against an Aβ-derived oligomer: Efforts toward a novel Alzheimer's disease immunotherapy Chelsea Marie Parrocha ¹, Adam Kreutzer ², Jesse Pascual ³, Cherie Stringer ³, Jennifer Nguyen ¹, Ashley Ith ¹, Elizabeth Head ³, James Nowick ^{2,1} ¹Department of Pharmaceutical Sciences, University of California Irvine - Irvine (United States), ²Department of Chemistry, University of California Irvine - Irvine (United States), ³Department of Pathology and Laboratory Medicine, University of California Irvine - Irvine (United States)</p>

Theme: Digital Health/E-Trials

	<p>P205: Assessment of deep learning algorithm of diagnosing Alzheimer's disease with Korean elderly Jong Bin Bae ¹, Ji Won Han ¹, Ki Woong Kim ^{1,2,3,4}, <u>Jun Sung Kim</u> ^{2,5} ¹Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Gyeonggido, Korea - Seongnam (Korea, Republic of), ²Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea - Seoul (Korea, Republic of), ³Department of Psychiatry, Seoul National University, College of Medicine, Seoul, South Korea - Seoul (Korea, Republic of), ⁴Department of Brain and Cognitive Science, Seoul National University College of Natural Sciences, Seoul, South Korea - Seoul (Korea, Republic of), ⁵Department of Neuropsychiatry, Seoul National University Bundang Hospital, Gyeonggido, Korea - Seongnam (Korea, Republic of)</p>
	<p>P206: A case-control clinical trial on the diagnostic performance for Alzheimer's Disease of a deep learning-based classification system using brain magnetic resonance imaging of Korean elderly <u>Jun Sung Kim</u> ^{1,2}, Jong Bin Bae ¹, Subin Lee ³, Ji Won Han ⁴, Ki Woong Kim ^{4,5,2} ¹Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea - Seongnam (Korea, Republic of), ²Institute of Human Behavioral Medicine, Seoul National University Medical Research Center, Seoul, Korea - Seoul (Korea, Republic of), ³Department Of Electrical And Computer Engineering, Seoul National University, Seoul, Korea - Seoul (Korea, Republic of), ⁴Department Of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea - Seoul (Korea, Republic of), ⁵Department of Psychiatry, Seoul National University, College of Medicine, Seoul, South Korea - Seoul (Korea, Republic of)</p>
	<p>P207: The Effect of Home-based Cognitive Training Using Workbook and Tablet PC in Presenile Dementia Patients <u>Jay Kwon</u> ¹, Kyeongsoo Lee ², Tae-You Kim ³, Tae-Kyeong Eom ¹ ¹Department Of Neurology, Changwon Fatima Hospital - Changwon (Korea, Republic of),</p>

	<p>²Department Of Neurology, Samsung Medical Center - Changwon (Korea, Republic of), ³Department Of Neurology, Busan Wilis Hospital - Busan (Korea, Republic of)</p>
	<p>P208: Efficacy of the ‘Finger-to-brain’ game on cognitive function of older adults with mild cognitive impairment: a randomized controlled crossover trial <u>Ji Won Han</u>^{1,2}, Dong Gyu Moon¹, Jung Uk Shin¹, Yeseung Park³, Min Jeong Kwon³, Hae In Kim³, Woori Moon¹, Dae Jong Oh^{4,2}, Jong Bin Bae^{1,2}, Ki Woong Kim^{5,2,3} ¹Department Of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam-Si (Korea, Republic of), ²Department of Psychiatry, Seoul National University College of Medicine - Seoul (Korea, Republic of), ³Department Of Brain And Cognitive Science, Seoul National University College Of Natural Sciences - Seoul (Korea, Republic of), ⁴Department Of Psychiatry, Smg-Snu Boramae Medical Center - Seoul (Korea, Republic of), ⁵Department Of Neuropsychiatry, Seoul National University Bundang Hospital - Seongnam-si (Korea, Republic of)</p>
	<p>P209: Feasibility, acceptability, and adherence of a remote smartphone-based self-assessment of cognition, function, and behavior in early Alzheimer’s disease <u>Thanneer Malai Perumal</u>¹, Arnaud Wolfer¹, Miguel Veloso², Irma T. Kurniawan¹, Gollou Keita³, Niels Hagenbuch⁴, Beijue Shi⁵, Foteini Orfanidou⁶, David Watson⁷, Mercè Boada Rovira⁸, Kirsten I. Taylor² ¹Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd - Basel (Switzerland), ²Roche Pharma Research And Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), ³Cytel Inc., - Geneve (Switzerland), ⁴Global Product Development Data And Statistical Sciences, F. Hoffmann-La Roche Ltd.- Basel (Switzerland), ⁵Global Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), ⁶Global Product Development, Personalized Healthcare, Digital Health, F. Hoffmann-La Roche Ltd., - Basel (Switzerland), ⁷Alzheimer’s Research And Treatment Center - Wellington (United States), ⁸Networking Research Center On Neurodegenerative Diseases (ciberned), Instituto De Salud Carlos Iii - Madrid (Spain)</p>
	<p>P210: Effect of internet-based mindfulness training on cognitive and psychological well-being and EEG brain activity in the elderly: preliminary results <u>Samantha Galluzzi</u>¹, Mariangela Lanfredi¹, Alberto Chiesa², Cristina Festari¹, Serena Meloni¹, Roberta Rossi¹, Evita Tomasoni¹, Davide Moretti¹, Michela Pievani¹ ¹IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli - Brescia (Italy), ²Istituto Mente e Corpo and Associazione di Psicologia Cognitiva - Scuola di Psicoterapia Cognitiva - Bologna, Rome (Italy)</p>
	<p>P211: Increasing Study Power via Frequent Speech-Based Assessments of Cognition <u>Gabriela Stegmann</u>¹, Shira Hahn¹, Julie Liss¹, Visar Berisha¹, Kimberly Mueller² ¹Arizona State University and Aural Analytics - Scottsdale, Az (United States), ²niversity of Wisconsin - Madison - Madison, Wi (United States)</p>
	<p>P212: A Multimodal Deep Learning Approach to Prediction of Cognitive Decline and its Potential Application in Clinical Trials for Alzheimer’s Disease <u>Caihua Wang</u>¹, Yuanzhong Li¹, Hiroyuki Yamaguchi², Hisateru Tachimori³, Atsushi Sekiguchi⁴, Yuichi Yamashita² ¹Imaging Technology Center, FUJIFILM Corporation - Kanagawa (Japan), ²Department of Information Medicine, National Institute of Neuroscience, National Center of Neurology and Psychiatry - Tokyo (Japan), ³Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry - Tokyo (Japan), ⁴Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry - Tokyo (Japan)</p>

	<p>P213: Preliminary Results of a Digital Pilot to Improve AD Trial Retention by Managing Caregiver Stress Rosemary Laird ^{1,2}, <u>Jessica Branning</u> ¹ ¹<i>ClinCloud Clinical Trials - Viera (United States)</i>, ²<i>Navigating Aging Needs LLC - Orlando (United States)</i></p>
	<p>P214: Brain Network Difference between Mild Cognitive Impairment and Alzheimer’s Disease Dementia Using EEG <u>Hong Yuseong</u> ¹, Baik Kyoungwon ², Park Ukeob ¹, Ye Byoung Seok ², Kang Seung Wan ¹ ¹<i>iMediSync Inc. - Seoul (Korea, Republic of)</i>, ²<i>Yonsei University College of Medicine - Seoul (Korea, Republic of)</i></p>
	<p>P215: Using Ecological Momentary Assessment to Measure Real-World Effects of a Combined Computerized Cognitive and Functional Skills training Program in Mild Cognitive Impairment <u>Philip Harvey</u> ¹, Peter Kallestrup ², Sara Czaja ³ ¹<i>University of Miami Miller School of Medicine - Miami (United States)</i>, ²<i>i-Function - Miami (United States)</i>, ³<i>Weill Cornell Medical Center - New York (United States)</i></p>
	<p>P216: The effects of home-based cognitive intervention with chat-bot on brain function in patients with amnesic mild cognitive impairment <u>Geon Ha Kim</u> ¹, Bori Kim ¹, Jee Hyang Jeong ¹ ¹<i>EwhaW.University - Seoul (Korea, Republic of)</i></p>
	<p>P217: Remote computer-based cognitive training: short- and long-term benefits on cognition and daily living in patients with Alzheimer's disease. <u>Samar Dimachki</u> ¹, Franck Tarpin-Bernard ², Stéphanie De Chalvron ², Bernard Croisile ³, Hanna Chainay ¹ ¹<i>Laboratoire d’Étude des Mécanismes Cognitifs, Université Lyon 2 - Lyon (France)</i>, ²<i>Scientific Brain Training SA - Lyon (France)</i>, ³<i>Service de Neuropsychologie, Centre Mémoire de Ressource et de Recherche de Lyon, Hôpital Neurologique - Lyon (France)</i></p>
	<p>P218: Taking care of family dementia caregivers: A qualitative examination of patient perspectives and perceived health outcomes after receiving usual care and after a digitally supported care management program <u>Olga Klein</u> ¹, Antonia Karras ², Wolfgang Hoffmann ^{3,4}, Stefan Teipel ^{1,2}, Ingo Kilimann ^{1,2} ¹<i>Deutsches Zentrum fuer Neurodegenerative Erkrankungen - Rostock (Germany) - Rostock (Germany)</i>, ²<i>Clinic for Psychosomatics and Psychotherapy, University Medical Center Rostock - Rostock (Germany)</i>, ³<i>Deutsches Zentrum fuer Neurodegenerative Erkrankungen - Greifswald (Germany)</i>, ⁴<i>Institute for Community Medicine, Section Epidemiology and Community Health, University Medicine Greifswald - Greifswald (Germany)</i></p>
	<p>P219: Intuition: a brain health study using multimodal digital biomarkers to decipher cognitive profiles of individuals at-risk for Alzheimer’s and related dementias <u>Monroe Butler</u> ¹, Anton Porsteinsson ², Sean Kenny ¹, Hansen Lenyoun ³, Matt Hobbs ¹, Roland Brown ¹, Matt Bianchi ³, James Williams ¹, Audrey Gabelle ¹, Shibeshih Belachew ¹, Intuition Study Scientific Committee Intuition Study Scientific Committee ¹ ¹<i>Biogen - Cambridge (United States)</i>, ²<i>University of Rochester Medical Center - Rochester (United States)</i>, ³<i>Apple - Cupertino (United States)</i></p>

	<p>P220: Cognitive health in underrepresented populations: early learnings from the Intuition brain health study</p> <p><u>Rhoda Au</u>¹, Monroe Butler², Hanson Lenyoun³, Sean Kenny², Roland Brown², Paramita Saha-Chaudhuri², Matt Bianchi³, James Williams², Audrey Gabelle², Shibeshih Belachew², Intuition Study Scientific Committee Intuition Study Scientific Committee²</p> <p>¹<i>Boston University School of Medicine - Boston (United States)</i>, ²<i>Biogen - Cambridge (United States)</i>, ³<i>Apple - Cupertino (United States)</i></p>
	<p>P221: Analyzing Facial Expressions and Poses Captured During Video Chats for Early Identification of MCI - Proof of Concept Study: I-CONNECT Project</p> <p><u>Muath Alsuhaibani</u>¹, Ali Pourramezan Fard¹, Hiroko Dodge^{2,3}, Mohammad Mahoor¹</p> <p>¹<i>School of Electrical and Computer Engineering, University of Denver - Denver (United States)</i>, ²<i>Layton Aging and Alzheimer's Disease Center, Oregon Health & Science University - Portland (United States)</i>, ³<i>Oregon Center for Aging and Technology (ORCATECH), Oregon Health & Science University - Portland (United States)</i></p>
	<p>P222: Using AI and Natural Language Processing Algorithms to Screen Older Adults with Mild Cognitive or Early Alzheimer's Disease</p> <p>Stephanie Melgar-Donis^{1,2}, Jarid Siewierski³, Rohola Zandie^{1,3}, Daniel Pittman¹, Lombe Chileshe¹, Hojjat Abdollahi³, Maryam Habibi³, Brock Soicher³, Eshrat Emamian³, <u>Mohammad Mahoor</u>^{3,4}</p> <p>¹<i>University of Denver - Denver (United States)</i>, ²<i>DreamFace Technologies, LLC</i>, ³<i>DreamFace Technologies, LLC - Centennial, Co (United States)</i>, ⁴<i>Univesrity of Denver - Denver (United States)</i></p>